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Abstract 
Background: Despite its high prevalence, opioid-induced constipation (OIC) remains under-recognised and 
undertreated, and its true impact on patients’ wellbeing and quality of life (QoL) may be underestimated. 
Methods: A quantitative, questionnaire-based international survey was conducted. Results: Weak-opioid 
users appear to be as bothered by constipation as strong-opioid users, despite it causing less-severe physical 
symptoms and impact on QoL. Strong-opioid users meeting the new Rome IV criteria for OIC appear to 
experience greater symptomatic and biopsychosocial burden from constipation than those who did not 
satisfy these criteria. A substantial proportion of respondents are dissatisfied with their current constipation 
treatment and find balancing the need for adequate pain relief with constipation side effects challenging. 
Consequently, many fail to adhere to their prescribed treatment regimens, or resort to using suboptimal 
strategies, e.g. reducing their opioid intake, to relieve constipation. Many healthcare professionals do not 
adequately counsel their patients about constipation as a common side effect of opioid use. Conclusions: 
Findings suggest that both weak- and strong-opioid users suffer comparable bother and decreased QoL, 
Rome IV criteria can identify patients with more-severe OIC, but may underdiagnose patients showing fewer 
symptoms, and increased education is needed to manage patients’ expectations and enable improved OIC 
self-management. 
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Key summary 
1. Summarise the established knowledge on this subject 
• Although constipation is a common side effect of opioid use, even with the concomitant use of 
laxatives, opioid-induced constipation (OIC) remains under-recognised and undertreated. 
• There is evidence to suggest that the impact of OIC on patients’ overall wellbeing and quality of life 
may be underestimated by healthcare professionals. 
• The recently published Rome IV diagnostic criteria for OIC provide a valuable tool for use in clinical 
practice; however, data are awaited on the value of these new criteria in the assessment of patients 
with OIC in the real-life setting. 
• A better understanding of the unmet needs of patients with OIC would be valuable to improve the 
recognition and management of this condition. 
2. What are the significant and/or new findings of this study? 
• Both weak- and strong-opioid users experience a considerable biopsychosocial burden caused by 
constipation, and the impact of OIC on users of weak opioids should not be underestimated. 
• Findings from this survey suggest that the new Rome IV criteria can identify patients with more 
severe OIC, but may underdiagnose patients with fewer/milder symptoms. 
• A substantial proportion of opioid users are not satisfied with their current constipation treatment 
and find balancing the need for adequate pain relief with constipation side effects challenging. This 
can lead to poor adherence with prescribed treatment regimens, or the use of suboptimal strategies 
to relieve constipation. 
• This survey highlighted a need for improved counselling for strong-opioid users, particulars regarding 
constipation as a potential side effect of opioid use. 
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Introduction 
In recent years, the worldwide use of opioids has increased significantly.
1
 Constipation is a common side 
effect of opioid use, and can affect up to 81% of patients, even with the concomitant use of laxatives.
2
 
Despite this, opioid-induced constipation (OIC) remains under-recognised and undertreated.
3
 Recently 
published Rome IV diagnostic guidance for functional gastrointestinal disorders now includes diagnostic 
criteria for OIC.
4
 While this is a much-needed step towards improving recognition of this condition, data are 
awaited on the value of these new criteria in the assessment of patients with OIC in real-life clinical practice. 
OIC has a negative impact on patients’ wellbeing, affecting daily activities, work productivity and health-
related quality of life,
2
 and is also associated with increased utilisation of healthcare resources.
5
 Available 
laxative therapies for OIC leave the patient with significant residual symptoms, which may lead them to 
adjust or stop their opioid intake in order to have a bowel movement, unless effectively counselled.
3, 6
 The 
management of OIC is often hampered by factors including a lack of understanding and recognition among 
healthcare professionals (HCPs) of the potential morbidity associated with this condition. It is not clear 
whether there is any difference in the biopsychosocial disease burden of constipation in patients using either 
strong or weak opioids. There may also be a perception that strong-opioid use is associated with more 
severe side effects, and that these also occur at a higher frequency, compared with weak-opioid use, 
highlighting a need to further our understanding of the burden of OIC in users of strong or weak opioids. 
Poor communication between HCPs and patients may be a further potential barrier to the effective 
management of OIC. Current guidance recommends that in addition to laxative use, first-line therapy should 
include non-pharmacological approaches, such as lifestyle modification and consumption of fibre-rich food. 
Therefore, good communication between the patient and HCP is key,
7-9
 to encourage uptake and adherence 
to these measures. Studies in a variety of chronic disease conditions have demonstrated a link between 
effective patient engagement, management of functional symptoms and positive health outcomes.
10
 For 
example, an individualised self-care education programme, with and without peak flow monitoring, 
improved lung function in patients with asthma;
11
 patients on a group-based self-management programme 
for multiple sclerosis reported improvements in health-related quality of life,
12
 and disease-specific self-help 
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groups were associated with improvements in self-reported general health status in patients with arthritis.
13
 
It would be valuable to gain a better understanding of the information-seeking behaviour of patients with 
OIC, in order to determine the optimal approach to education and timely communication of appropriate 
information. 
In an attempt to address some of the unmet needs in the management of OIC, this international survey was 
conducted to investigate whether long-term users of strong opioids (e.g. buprenorphine, fentanyl) with 
Rome IV-positive OIC differ in biopsychosocial disease burden versus those with constipation who do not 
satisfy the Rome IV criteria, and assess the impact of strong or weak (e.g. codeine, dihydrocodeine) opioids 
in patients with chronic pain who have constipation. The use of counselling resources, information seeking 
and sources of support in patients with constipation caused by the use of strong opioids was also explored. 
Methodology 
Two separate quantitative, questionnaire based, online surveys were conducted by Insight Dojo, Guildford, 
UK. One survey took place in France, Germany, Italy, Spain and the UK in respondents aged ≥40 years who 
were using strong opioids. A second survey was conducted in Germany, Spain and the UK in respondents 
aged ≥18 years who were using weak opioids. 
Respondents were recruited using two different types of online panel: (1) a large panel representative of the 
population in each market, and (2) targeted chronic pain panels e.g. a ‘rheumatoid arthritis’ panel. 
Respondents had largely non-cancer-related chronic pain that was being managed with opioids, and OIC 
(defined as having ≤2 bowel movements per week, and expressing bother from constipation or 
dissatisfaction with current treatments for constipation). All individuals who joined the panels consented to 
participate in the online survey. The International Chamber of Commerce/European Society for Opinion and 
Marketing Research (ICC/ESOMAR) International Code on Market, Opinion and Social Research and Data 
Analytics,
14
 and all local country codes of conduct for market research, were adhered to when conducting 
the survey. All respondents received a very small incentive for taking part in the survey, which ranged from 
€1.00–1.50 in France, Germany, Italy and Spain, and £0.75–1.00 in the UK. The survey questionnaires were 
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developed by Insight Dojo in collaboration with Shionogi and assessed past medical history, opioid use, 
treatment and treatment-seeking behaviour, symptoms, burden of disease, and effects of constipation on 
quality of life (see Appendices 1 and 2). The survey did not capture any self-reports of severity; rather, the 
analyses used objective measures of severity which were applied to self-reported symptoms and 
experiences. 
To satisfy the Rome IV criteria for OIC, respondents who were users of strong opioids must have had new or 
worsening symptoms of constipation when initiating, changing or increasing opioid therapy plus 2 or more of 
the following symptoms defining functional constipation, with a frequency cut-off of 25%: straining, lumpy or 
hard stools, sensation of incomplete evacuation, sensation of anorectal blockage, use of manual 
manipulation to facilitate defaecation or <3 spontaneous bowel movements per week.
15
 
To ensure comparability, only respondents aged ≥40 years from Germany, Spain and the UK were included in 
the analyses of strong- versus weak-opioid users. Analyses conducted to investigate approaches to the 
management of OIC, perceptions of treatment and counselling/information-seeking behaviour were 
conducted in the overall population of strong-opioid users. 
Descriptive data were presented as proportions (%) of total subgroup populations, and Z-tests were 
performed to establish significance between subgroups. A p value <0.05 was defined as statistically 
significant. 
Results 
Analysis of Rome IV versus non-Rome IV subgroups of strong-opioid users 
A total of 18,995 respondents from a nationally representative panel entered the survey from France, 
Germany, Italy, Spain and the UK, with 2016 eligible (i.e. overall strong-opioid population). Of these, 951 
(47%) met the Rome IV diagnostic criteria for OIC. 
Baseline demographics and characteristics of the Rome IV OIC and non-Rome IV subgroups are shown in 
Table 1. Compared with non-Rome IV respondents, significantly more respondents who satisfied the 
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Rome IV criteria reported physical effects of OIC, with the main symptoms being ‘straining to pass stools’, 
‘abdominal bloating’ and ‘sensation of blockage/bowel obstruction’ (Figure 1A). A significantly greater 
proportion of Rome IV respondents felt emotional and psychological symptoms caused by OIC than did 
non-Rome IV respondents, with feelings of frustration, dependence and anxiety/worry being key (Figure 2A). 
While all respondents reported an impact of OIC on daily life/relationships, this was significantly greater in 
the Rome IV group who cited ‘excessive time spent in bathroom’, ‘difficulty following normal routine’ and 
‘difficulty being intimate with others’ as key factors impacting on their wellbeing (Figure 3A). 
Overall, significantly more Rome IV than non-Rome IV respondents experienced quite a lot/a great deal of 
bother from their OIC symptoms (42% vs 31%; p<0.0001). 
Analysis of strong- versus weak-opioid users 
For the strong-opioid population, a total of 13,641 respondents from a nationally representative panel 
entered the survey from Germany, Spain and the UK, with 545 eligible (equating to a response rate of 4.0%). 
The remaining 665 respondents for the strong-opioid analysis were sourced from a target panel. For the 
weak-opioid population, 3,856 respondents from a nationally representative panel entered the survey from 
Germany, Spain and the UK, with 663 included in the final analyses (for a response rate of 17.2%). 
Baseline demographics and characteristics of the populations of strong- (n=1210) and weak- (n-663) opioid 
users aged ≥40 years are shown in Table 1. Compared with the weak-opioid population, more respondents in 
the strong-opioid population were male (48% vs 37%, respectively) and younger (81% vs 71% aged <60 years, 
respectively). The majority of strong-opioid users were taking opioids for chronic back pain, while weak-
opioid users had a variety of reasons for requiring pain relief. In general, strong-opioid users had started 
taking opioids more recently than weak-opioid users, with 40% of the latter group receiving their first opioid 
prescription ≥5 years ago (vs 24% of strong-opioid users). 
A comparable degree of bother from constipation symptoms was felt by both weak- and strong-opioid users, 
with 38% and 40% of respondents, respectively, stating that constipation bothered them quite a lot/a great 
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deal (between-group comparison, p=0.40). This pattern was reflected in the main psychological symptoms 
experienced due to constipation (i.e. frustration, dependence, anxiety) (Figure 2B). 
The incidence of more-common physical symptoms (i.e. straining to pass stools, abdominal bloating, 
sensation of bowel blockage/obstruction) was similar in the strong- and weak-opioid groups. However, 
weak-opioid users experienced significantly fewer less-common physical symptoms of constipation 
compared with strong-opioid users, including stomach cramps, rectal burning and haemorrhoids (all p<0.02) 
(Figure 1B). Moreover, the impact of constipation on quality of life/social symptoms was felt significantly less 
by weak-opioid users compared with users of strong opioids (Figure 3B). 
Approaches to the management of OIC and perceptions of treatment in strong-opioid users 
Around one-third of respondents found it difficult to combine management of pain relief with constipation 
symptoms and disliked having to balance between them (32%) (Figure 4A). While 23% of respondents were 
neither satisfied nor dissatisfied and 46% were very or somewhat satisfied with the effectiveness of their 
current constipation treatment, nearly one-fifth (18%) were very or somewhat dissatisfied (data missing for 
13% of respondents), and only 42% strictly adhered to prescribed treatment regimens, with 30% researching 
other treatment options (Figure 4A). A significant proportion of respondents (44%) admitted that their 
constipation becomes so bothersome that they have to combine different methods to relieve it, and 40% 
often cut down their opioid medication (Figure 4B) or even skip it entirely (9%) to relieve constipation 
(Figure 5A). This is despite more than half (57%) stating they would prefer not to reduce their opioid 
medication, if possible (Figure 4B). To manage their constipation, respondents regularly used a variety of 
approaches, including dietary measures (48%), exercise (23%) and single (32%) or multiple (15%) laxative 
treatments (Figure 5B). 
Counselling and information-seeking behaviour among strong-opioid users 
Only 41% of respondents reported that their HCPs had warned them about constipation as a potential side 
effect of opioid use (Figure 6). Almost two-thirds of respondents (64%) reported that their HCP was the main 
information source on OIC. Other common sources of information were online search engines (45%), health 
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forums (28%), blogs (12%) and other online resources (8%), as well as leaflets in their HCP’s workplace (21%), 
television (20%) and newspapers/magazines (19%). Respondents also sometimes received advice from their 
partners, friends and family members (cited by 16%, 16% and 14% of respondents, respectively). Although 
49% of respondents stated that they would have liked their HCP to provide more information about OIC, 48% 
preferred to deal with constipation on their own, rather than discuss it with their HCP (Figure 4B). 
Discussion and conclusions 
Despite its high prevalence among opioid users, OIC remains under-recognised and undertreated, and its 
true impact on patients’ overall wellbeing and quality of life may be underestimated. This survey found that 
users of both weak and strong opioids experience a considerable biopsychosocial burden caused by 
constipation. Subjectively, weak-opioid users appear to be as bothered by their constipation as strong-opioid 
users, despite it causing less-severe physical symptoms and a less-drastic impact on quality of life. This may 
reflect strong-opioid users having more serious underlying pain conditions and/or requiring other 
concomitant therapies, which may cause debilitating side effects of greater concern than constipation, 
compared with weak-opioid users. 
To our knowledge, the present analysis is the first time that the Rome IV criteria for OIC have been evaluated 
in a real-world setting. Findings showed that compared with strong-opioid users who did not satisfy the 
Rome IV criteria, those who did meet Rome IV criteria appeared to experience greater symptomatic and 
biopsychosocial burden from their constipation. This suggests that Rome IV criteria can identify patients with 
more severe OIC, but may underdiagnose patients with constipation who do not demonstrate the full scale 
of symptoms. Further investigation of these preliminary findings is needed. 
Overall, 18% of strong-opioid users who participated in this survey are not satisfied with their current 
constipation treatment and 32% report that they find it challenging to balance the need for adequate pain 
relief with constipation side effects. Consequently, many fail to adhere to their prescribed treatment 
regimens, or resort to using suboptimal strategies, such as reducing their opioid intake, to relieve 
constipation. Similarly, patients with cancer pain using opioids frequently experience burdensome 
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constipation.
16
 Poor adherence with opioid analgesic regimens has been reported in 49–70% of patients,
17
 
with some stating that they would rather endure pain than experience the constipation associated with their 
opioid treatment.
16
 
Opioids are prescribed for the management of pain by different types of clinicians across both primary and 
secondary care, and approaches to counselling and follow-up of patients may be very different. Research 
shows that patients who understand more about their disease often have improved health outcomes and 
use fewer healthcare resources. These benefits are even greater when patients are empowered and feel 
responsible for self-managing their condition.
18
 The initial contact with an HCP provides an opportunity for 
patients to ask questions, while also allowing the HCP to identify the patient’s individual needs in terms of 
education.
19
 This may be influenced by the patient’s perceptions, expectations and concerns, as well as 
factors affecting adherence with the prescribed treatment.
20
 This survey highlighted that patients’ 
expectations with regard to the provision of information are not being met, with almost half stating that they 
would have liked their HCP to provide more information about OIC. Advice and information should be 
tailored appropriately for patients initiating opioids versus those already established on treatment, and 
should address all biopsychosocial aspects of the burden of OIC. 
While most respondents would like more support from their HCP, a substantial proportion prefer to deal 
with constipation on their own, perhaps due to embarrassment or resignation to the symptoms of OIC. 
Previous research has found that over one-third of patients do not raise the subject of OIC with their HCP,
21
 
and one-fifth feel uncomfortable talking about their condition with an HCP, most often due to 
embarrassment.
22
 Therefore, HCPs should proactively raise the topic of OIC rather than wait for patients to 
initiate discussions, and should be attentive to how patients express the physical, psychological and practical 
impact of OIC.
5
 
A recent observational study showed that drug safety is a major focus of patients who are prescribed new 
medicines for the long-term treatment of chronic conditions. This is particularly important, given that a 
substantial proportion of patients cite safety issues as a reason for discontinuing treatment.
20
 The present 
survey found that many HCPs are not counselling patients adequately about constipation as a common 
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potential side effect of opioid use, highlighting the need for increased education to manage patients’ 
expectations and enable improved self-management of their condition. The presentation of repeat-opioid 
users at pharmacies may provide a valuable opportunity for patient engagement, reinforcing information 
provided by the physician, and for counselling patients who are non-adherent with optimal treatment 
regimens.
23
 
Digital technologies are increasingly being used to support patient care in the management of chronic 
diseases such as asthma, chronic obstructive pulmonary disorder, diabetes, heart failure and hypertension. 
They can provide education to improve self-management, enable monitoring, and facilitate contact with 
HCPs (e.g. via telephone support and follow-up).
24
 In this survey, patients reported using online search 
engines and online health forums as common sources of information, suggesting this group may be an 
appropriate target for digital educational interventions. 
This survey had several limitations. The information provided by participants was self-reported and was not 
verified from medical records or by their HCP. As such, it may have been subject to recall bias. There is also a 
possibility that patients unhappy with their OIC treatment may have been more motivated to participate in 
the survey than those who were satisfied. Any potential impact of the strong- and weak-opioid users being 
recruited via two different surveys is not known. Panel respondents were offered a financial incentive to 
participate in the survey; however, given the small monetary amount, it is not expected that this would be 
associated with any significant bias. 
In conclusion, the increasing use of opioids globally means that a growing number of patients will experience 
OIC, driving the need for improved recognition and management of this condition. HCPs should not 
underestimate the morbidity associated with OIC, in particular the degree of bother caused by constipation 
in users of weak opioids, which is comparable to that of strong-opioid users. Approaches to counselling 
should be tailored to the individual patient’s needs and preferences, and should include education on 
constipation as a common potential side effect of opioid use and how this can be effectively managed, as 
well as addressing the biopsychosocial aspects of the burden of constipation. The recently published Rome IV 
diagnostic criteria provide a valuable tool for use in clinical practice. However, findings from this survey 
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suggest that these criteria may be more effective in diagnosing patients with severe OIC, compared with 
those showing fewer symptoms. 
 
Acknowledgements 
This survey was funded by Shionogi. Editorial support in the development of this manuscript was provided by 
James Reed PhD of Blue Heeler Ltd, and funded by Shionogi in accordance with Good Publication Practice 
(GPP3) guidelines (http://www.ismpp.org/gpp3). 
Page 13 of 64
htpp://mc.manuscriptcentral.com/UEGH
United European Gastroenterology Journal
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
13 
 
 References 
1. O'Brien T, Christrup LL, Drewes AM, et al. European Pain Federation position paper on appropriate 
opioid use in chronic pain management. Eur J Pain 2017; 21: 3-19. DOI: 10.1002/ejp.970. 
2. Webster LR. Opioid-Induced Constipation. Pain Med 2015; 16 Suppl 1: S16-21. DOI: 
10.1111/pme.12911. 
3. Gupta A. Improving the recognition and diagnosis of opioid-induced constipation in clinical practice. J 
Fam Pract 2015; 64. 
4. Mearin F, Lacy BE, Chang L, et al. Bowel Disorders. Gastroenterology 2016: [Epub ahead of print]. DOI: 
10.1053/j.gastro.2016.02.031. 
5. Epstein RS, Teagarden JR, Cimen A, et al. When People with Opioid-Induced Constipation Speak: A 
Patient Survey. Adv Ther 2017; 34: 725-731. DOI: 10.1007/s12325-017-0480-4. 
6. LoCasale RJ, Datto C, Margolis MK, et al. Satisfaction with Therapy Among Patients with Chronic 
Noncancer Pain with Opioid-Induced Constipation. J Manag Care Spec Pharm 2016; 22: 246-253. DOI: 
10.18553/jmcp.2016.22.3.246. 
7. Dorn S, Lembo A and Cremonini F. Opioid-induced bowel dysfunction: epidemiology, pathophysiology, 
diagnosis, and initial therapeutic approach. Am J Gastroenterol Suppl 2014; 2: 31-37. DOI: 
10.1038/ajgsup.2014.7. 
8. Drewes AM, Munkholm P, Simren M, et al. Definition, diagnosis and treatment strategies for opioid-
induced bowel dysfunction-Recommendations of the Nordic Working Group. Scand J Pain 2016; 11: 111-
122. DOI: 10.1016/j.sjpain.2015.12.005. 
9. Kumar L, Barker C and Emmanuel A. Opioid-induced constipation: pathophysiology, clinical 
consequences, and management. Gastroenterol Res Pract 2014; 2014: 141737. DOI: 
10.1155/2014/141737. 
10. Simmons LA, Wolever RQ, Bechard EM, et al. Patient engagement as a risk factor in personalized health 
care: a systematic review of the literature on chronic disease. Genome Med 2014; 6: 16. DOI: 
10.1186/gm533. 
Page 14 of 64
htpp://mc.manuscriptcentral.com/UEGH
United European Gastroenterology Journal
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
14 
 
11. Huang TT, Li YT and Wang CH. Individualized programme to promote self-care among older adults with 
asthma: randomized controlled trial. J Adv Nurs 2009; 65: 348-358. DOI: 10.1111/j.1365-
2648.2008.04874.x. 
12. Barlow J, Turner A, Edwards R, et al. A randomised controlled trial of lay-led self-management for 
people with multiple sclerosis. Patient Educ Couns 2009; 77: 81-89. DOI: 10.1016/j.pec.2009.02.009. 
13. Goeppinger J, Armstrong B, Schwartz T, et al. Self-management education for persons with arthritis: 
Managing comorbidity and eliminating health disparities. Arthritis Rheum 2007; 57: 1081-1088. DOI: 
10.1002/art.22896. 
14. International Chamber of Commerce/European Society for Opinion and Marketing Research 
(ICC/ESOMAR). International Code on Market, Opinion and Social Research and Data Analytics, 
https://www.esomar.org/uploads/public/knowledge-and-standards/codes-and-
guidelines/ICCESOMAR_Code_English_.pdf (2016, accessed March 2018). 
15. Simren M, Palsson OS and Whitehead WE. Update on Rome IV Criteria for Colorectal Disorders: 
Implications for Clinical Practice. Curr Gastroenterol Rep 2017; 19: 15. DOI: 10.1007/s11894-017-0554-0. 
16. Coyne KS, Sexton C, LoCasale RJ, et al. Opioid-Induced Constipation among a Convenience Sample of 
Patients with Cancer Pain. Front Oncol 2016; 6: 131. DOI: 10.3389/fonc.2016.00131. 
17. Nguyen LM, Rhondali W, De la Cruz M, et al. Frequency and predictors of patient deviation from 
prescribed opioids and barriers to opioid pain management in patients with advanced cancer. J Pain 
Symptom Manage 2013; 45: 506-516. DOI: 10.1016/j.jpainsymman.2012.02.023. 
18. Talboom-Kamp EP, Verdijk NA, Harmans LM, et al. An eHealth Platform to Manage Chronic Disease in 
Primary Care: An Innovative Approach. Interact J Med Res 2016; 5: e5. DOI: 10.2196/ijmr.4217. 
19. Graarup J, Ferrari P and Howard LS. Patient engagement and self-management in pulmonary arterial 
hypertension. Eur Respir Rev 2016; 25: 399-407. DOI: 10.1183/16000617.0078-2016. 
20. Vucicevic KM, Miljkovic BR, Golubovic BC, et al. Expectations, concerns, and needs of patients who start 
drugs for chronic conditions. A prospective observational study among community pharmacies in Serbia. 
Eur J Gen Pract 2017: 1-7. DOI: 10.1080/13814788.2017.1388778. 
Page 15 of 64
htpp://mc.manuscriptcentral.com/UEGH
United European Gastroenterology Journal
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
15 
 
21. Coyne KS, LoCasale RJ, Datto CJ, et al. Opioid-induced constipation in patients with chronic noncancer 
pain in the USA, Canada, Germany, and the UK: descriptive analysis of baseline patient-reported 
outcomes and retrospective chart review. Clinicoecon Outcomes Res 2014; 6: 269-281. DOI: 
10.2147/CEOR.S61602. 
22. Rauck RL, Hong KJ and North J. Opioid-Induced Constipation Survey in Patients with Chronic Noncancer 
Pain. Pain Pract 2017; 17: 329-335. DOI: 10.1111/papr.12445. 
23. Spadea T, Brusa P, Gnavi R, et al. [Community pharmacy; towards a new model.]. Recenti Prog Med 
2017; 108: 168-171. DOI: 10.1701/2681.27451. 
24. Wootton R. Twenty years of telemedicine in chronic disease management--an evidence synthesis. J 
Telemed Telecare 2012; 18: 211-220. DOI: 10.1258/jtt.2012.120219. 
Page 16 of 64
htpp://mc.manuscriptcentral.com/UEGH
United European Gastroenterology Journal
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
16 
 
Figure legends 
Figure 1. Physical symptoms of constipation experienced by patients using opioids, stratified by Rome IV 
with OIC vs non-Rome IV with constipation (A) and weak- vs strong-opioid use (B) subgroups 
*p<0.05 versus non-Rome IV with constipation subgroup; **p<0.02 versus weak-opioid users 
OIC, opioid-induced constipation 
Figure 2. Emotional and psychological symptoms of constipation experienced by patients using opioids, 
stratified by Rome IV with OIC vs non-Rome IV with constipation (A) and weak- vs strong-opioid use (B) 
subgroups 
*p<0.05 versus non-Rome IV with constipation subgroup; **p<0.05 versus weak-opioid users 
OIC, opioid-induced constipation 
Figure 3. Impact of constipation on quality of life and social interactions experienced by patients using 
opioids, stratified by Rome IV with OIC vs non-Rome IV with constipation (A) and weak- vs strong-opioid 
use (B) subgroups 
*p<0.05 versus non-Rome IV with constipation subgroup; **p<0.05 versus weak-opioid users 
OIC, opioid-induced constipation 
Figure 4. Respondents’ approaches to the management of constipation and perceptions of treatment 
(strong-opioid users; N=2016) 
HCP, healthcare professional 
Figure 5. Analgesia-related (A) and other (B) approaches used regularly by respondents to manage their 
constipation (strong-opioid users; N=2016) 
Figure 6. Counselling provided by HCPs when prescribing an opioid to respondents (strong-opioid users; 
N=2016) 
HCP, healthcare professional 
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Table 
Table 1. Survey respondents’ baseline demographics and characteristics 
Parameter, n (%) Overall strong-opioid 
population 
(5 countries) 
(N=2016) 
Strong-opioid population  
(3 countries) 
 
(n=1210) 
Weak-opioid population 
(3 countries) 
 
(n=663) 
Rome IV OIC subgroup 
(strong-opioid users) 
 
(n=951) 
Non-Rome IV with 
constipation subgroup 
(strong-opioid users) 
(n=1065) 
Age group, years 
40–49 
50–59 
60–69 
≥70 
 
928 (46) 
713 (35) 
312 (15) 
63 (3) 
 
544 (45) 
433 (36) 
194 (16) 
39 (3) 
 
210 (35) 
218 (36) 
140 (23) 
37 (6) 
 
443 (47) 
313 (33) 
158 (17) 
37 (4) 
 
485 (46) 
400 (38) 
154 (14) 
26 (2) 
Gender 
Male 
Female 
 
976 (48) 
1040 (52) 
 
576 (48) 
634 (52) 
 
224 (37) 
381 (63) 
 
467 (49) 
484 (51) 
 
509 (48) 
556 (52) 
Employment status 
Full-time/part-time/ self-
employed 
Unemployed 
Semi-retired/retired 
Student/in full-time 
training 
 
1443 (72) 
 
198 (10) 
372 (18) 
3 (<1) 
 
818 (68) 
 
125 (10) 
265 (22) 
2 (<1) 
 
324 (54) 
 
83 (14) 
198 (33) 
– 
 
680 (72) 
 
81 (9) 
188 (20) 
– 
 
763 (72) 
 
117 (11) 
184 (17) 
1 (<1) 
Single underlying 
condition that causes the 
most pain 
Chronic back pain 
Migraine 
Rheumatoid arthritis 
Osteoarthritis 
Fibromyalgia 
Joint pain 
Pain relating to cancer 
(not prostate cancer) 
 
 
 
586 (29) 
342 (17) 
255 (13) 
154 (8) 
142 (7) 
101 (5) 
34 (2) 
 
 
 
 
391 (32) 
178 (15) 
155 (13) 
60 (5) 
109 (9) 
67 (6) 
22 (2) 
 
 
 
 
160 (26) 
43 (7) 
43 (7) 
40 (7) 
44 (7) 
76 (13) 
4 (1) 
 
 
 
 
295 (31) 
141 (15) 
136 (14) 
80 (8) 
63 (7) 
47 (5) 
21 (2) 
 
 
 
 
291 (27) 
201 (19) 
119 (11) 
74 (7) 
79 (7) 
54 (5) 
13 (1) 
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Neuropathic pain related 
to diabetes 
Other 
24 (1) 
 
13 (<1) 
16 (1) 
 
9 (<1) 
– 
 
195 (32) 
8 (1) 
 
5 (<1) 
16 (2) 
 
8 (<1) 
Duration of underlying 
condition 
>3 months but <1 year 
1 to <3 years 
3 to <5 years 
5 to <10 years 
≥10 years 
 
 
167 (8) 
455 (23) 
450 (22) 
480 (24) 
464 (23) 
 
 
87 (7) 
223 (18) 
253 (21) 
312 (26) 
335 (28) 
 
 
30 (5) 
91 (15) 
101 (17) 
142 (23) 
241 (40) 
 
 
85 (9) 
224 (24) 
207 (22) 
221 (23) 
214 (23) 
 
 
82 (8) 
231 (22) 
243 (23) 
259 (24) 
250 (23) 
Current opioid use 
(multiple responses 
possible) 
Morphine 
Fentanyl 
Oxycodone 
Oxycodone + naloxone 
Buprenorphine 
Tapentadol 
Methadone 
Meperidine 
Hydromorphone 
Diamorphine 
Opium + acetaminophen 
Piritramide 
Levomethadone 
Co-codamol 
Tramadol 
Tilidine 
Tramadol + 
acetaminophen 
Dihydrocodeine 
Codeine 
Ketamine 
 
 
 
683 (34) 
634 (31) 
576 (29) 
273 (14) 
213 (11) 
178 (9) 
159 (8) 
137 (7) 
131 (6) 
50 (2) 
37 (2) 
18 (1) 
16 (1) 
– 
– 
– 
– 
 
– 
– 
– 
 
 
 
449 (37) 
253 (21) 
271 (22) 
192 (16) 
120 (10) 
108 (9) 
63 (5) 
137 (11) 
83 (7) 
50 (4) 
– 
18 (1) 
16 (1) 
– 
– 
– 
– 
 
– 
– 
– 
 
 
 
– 
– 
– 
– 
– 
– 
– 
– 
– 
– 
– 
– 
– 
323 (53) 
236 (39) 
77 (13) 
53 (9) 
 
34 (6) 
33 (5) 
11 (2) 
 
 
 
324 (34) 
310 (33) 
294 (31) 
118 (12) 
91 (10) 
79 (8) 
78 (8) 
62 (7) 
61 (6) 
30 (3) 
18 (2) 
10 (1) 
7 (1) 
– 
– 
– 
– 
 
– 
– 
– 
 
 
 
359 (34) 
324 (30) 
282 (26) 
161 (15) 
122 (11) 
99 (9) 
81 (8) 
75 (7) 
70 (7) 
20 (2) 
19 (2) 
8 (1) 
9 (1) 
– 
– 
– 
– 
 
– 
– 
– 
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Total percentages for each parameter may not equal 100 due to rounding. 
Pethidine 
Promethazine 
– 
– 
– 
– 
14 (2) 
<1 (1) 
– 
– 
– 
– 
Current laxative use 
(multiple responses 
possible) 
Stimulant laxative 
Osmotic agent 
Saline laxative 
Bulk-forming laxative 
Other (potentially non-
laxative) 
Emollient laxative 
Lubricant laxative 
Combination of laxatives 
Guanylate cyclase 2C 
agonist 
Serotonin agonist 
None 
 
 
 
867 (43) 
830 (41) 
322 (16) 
146 (7) 
125 (6) 
 
86 (4) 
60 (3) 
307 (15) 
20 (<1) 
 
9 (<1) 
254 (13) 
 
 
 
470 (39) 
467 (39) 
78 (6) 
44 (4) 
76 (6) 
 
76 (6) 
– 
264 (22) 
16 (1) 
 
7 (1) 
187 (15) 
 
 
 
86 (14) 
92 (15) 
19 (3) 
7 (1) 
9 (1) 
 
4 (1) 
– 
33 (5) 
3 (<1) 
 
– 
10 (2) 
 
 
 
434 (46) 
448 (47) 
161 (17) 
71 (7) 
58 (6) 
 
36 (4) 
30 (3) 
140 (15) 
9 (1) 
 
2 (<1) 
91 (10) 
 
 
 
433 (41) 
382 (36) 
161 (15) 
75 (7) 
67 (6) 
 
50 (5) 
30 (3) 
167 (16) 
11 (1) 
 
7 (1) 
163 (15) 
Time of first opioid 
prescription 
In the last ≤3 months 
>3 months but <1 year 
1 to <3 years 
3 to <5 years 
≥5 years 
 
 
204 (10) 
432 (21) 
632 (31) 
359 (18) 
389 (19) 
 
 
8 (8) 
228 (19) 
364 (30) 
234 (19) 
292 (24) 
 
 
27 (4) 
61 (10) 
150 (25) 
125 (21) 
242 (40) 
 
 
101 (11) 
205 (22) 
301 (32) 
157 (17) 
187 (20) 
 
 
103 (10) 
227 (21) 
331 (31) 
202 (19) 
202 (19) 
Constipation prior to 
opioid use 
Much/slightly better 
The same 
Much/slightly worse 
 
 
1158 (57) 
515 (26) 
343 (17) 
 
 
654 (54) 
322 (27) 
234 (19) 
 
 
348 (58) 
213 (35) 
44 (7) 
 
 
951 (100) 
0 (0) 
0 (0) 
 
 
207 (19) 
515 (48) 
343 (32) 
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Figure 1. Physical symptoms of constipation experienced by patients using opioids, stratified by Rome IV 
with OIC vs non-Rome IV with constipation (A) and weak- vs strong-opioid use (B) subgroups  
 
*p<0.05 versus non-Rome IV with constipation subgroup; **p<0.02 versus weak-opioid users  
 
OIC, opioid-induced constipation  
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Figure 2. Emotional and psychological symptoms of constipation experienced by patients using opioids, 
stratified by Rome IV with OIC vs non-Rome IV with constipation (A) and weak- vs strong-opioid use (B) 
subgroups  
 
*p<0.05 versus non-Rome IV with constipation subgroup; **p<0.05 versus weak-opioid users  
 
OIC, opioid-induced constipation  
 
115x156mm (300 x 300 DPI)  
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Figure 3. Impact of constipation on quality of life and social interactions experienced by patients using 
opioids, stratified by Rome IV with OIC vs non-Rome IV with constipation (A) and weak- vs strong-opioid 
use (B) subgroups  
 
*p<0.05 versus non-Rome IV with constipation subgroup; **p<0.05 versus weak-opioid users  
 
OIC, opioid-induced constipation  
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Figure 4. Respondents’ approaches to the management of constipation and perceptions of treatment 
(strong-opioid users; N=2016)  
 
HCP, healthcare professional  
 
112x153mm (300 x 300 DPI)  
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Figure 5. Analgesia-related (A) and other (B) approaches used regularly by respondents to manage their 
constipation (strong-opioid users; N=2016)  
 
85x86mm (300 x 300 DPI)  
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Figure 6. Counselling provided by HCPs when prescribing an opioid to respondents (strong-opioid users; 
N=2016)  
 
HCP, healthcare professional  
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Strong-opioid use questionnaire 
Country 
 UK 
 France 
 Italy 
 Germany 
 Spain 
This section includes a number of basic questions about your health and medication. This section will take 
approximately 5 minutes to complete, but all questions must be filled in in order to progress. 
Q1 
Do you, or any members of your immediate family, work for any of the following industries? 
 Advertising 
 Market research 
 PR or marketing industry 
 Healthcare or medical industry 
 Manufacture or sale of pharmaceutical products 
 None of these 
Q2 
How old are you? 
 
Q3 
Which, if any, of the following conditions do you suffer from? 
Select all that apply 
 Chronic back pain 
 Rheumatoid Arthritis 
 Osteoarthritis 
 Psoriatic Arthritis 
 Joint pain 
 Fibromyalgia  
 Neuropathic pain relating to diabetes  
 Neuropathic pain not relating to diabetes 
 Post herpetic neuralgia 
 Non herpetic neuralgia 
 Migraine 
 Headache 
 Pain relating to cancer  
      (excluding prostate cancer) 
 Shoulder pain/ stiffness 
 Neck pain 
 Hip/ pelvic pain 
 Carpal tunnel syndrome 
 Dental pain 
 Tendonitis 
 Pain from broken bones 
 Menstrual pain 
 Plantar fasciitis 
 Sprains or strains 
 Other pain condition (please specify)____________ 
 Prefer not to say 
 None of these 
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Q3a 
Which of the following types of cancer do you have? Select all that apply 
 Anal 
 Bladder 
 Bone 
 Bowel/Colon/Colorectal 
 Brain 
 Breast 
 Cervical 
 Esophageal 
 Hodgkin Lymphoma 
 Kidney (incl renal cell) 
 Leukemia 
 Liver 
 Lung 
 Melanoma 
 Mouth 
 Multiple Myeloma 
 Non Hodgkin Lymphoma 
 Ocular (eye) 
 Ovarian 
 Pancreatic 
 Penile 
 Prostate 
 Skin (Non-Melanoma) 
 Squamous cell cancer (head or neck) 
 Stomach 
 Testicular 
 Thyroid 
 Uterine 
 Other type of cancer 
 Prefer not to say 
Q4 
Which of these chronic pain conditions causes you the most severe pain i.e., the one for which you need the 
strongest pain treatment? 
Note that this list might not include all of the conditions that you indicated in the previous questions. 
 Chronic back pain 
 Rheumatoid Arthritis 
 Osteoarthritis 
 Joint pain 
 Neuropathic pain relating to diabetes 
 Post herpetic neuralgia 
 Migraine 
 Fibromyalgia 
 Pain relating to cancer (excluding prostate cancer) 
 Shoulder pain/ stiffness 
 Neck pain 
Q5 
When did you first begin to experience ___________________? 
 In the last 3 months 
 More than 3 months, but less than one year ago 
 1 year or more, but less than 3 years 
 3 years or more, but less than 5 years 
 5 years or more, but less than 10 years 
 10 years or more 
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Q6a 
Given below is a list of opioid drugs that people take for pain relief. 
 
Part 1 - Could you please select the ones that you are currently taking 
 
Part 2 - Could you please select the ones that you have tried before, but are not currently taking 
 Physeptone 
 Methadone 
 Oramorph 
 MST continus 
 Zomorph 
 Oxynorm 
 Oxycontin 
 Morphine Sulphate 
 Longtec 
 Sevredol 
 Morphgesic 
 Butrans 
 Palexia 
 Shortec 
 Temgesic 
 Lynlor 
 Targinact 
 Matrifen 
 Durogesic Dtrans 
 Oxycodone 
 Tephine 
 Reltebon 
 Pethidine 
 Oxylan 
 Diamorphine 
 Fencino 
 Transtec 
 Actiq 
 Palladone 
 Fentanyl 
 Abstral 
 Targin 
 Palexia 
 MST continus 
 Yantil 
 Durogesic 
 Oxycontin 
 Abstral 
 Actiq 
 Sevredol 
 Pecfent 
 Transtec 
 Fentanilo 
 Oxynorm 
 Effentora 
 Jurnista 
 Feliben 
 Metasedin 
 Instanyl 
 Fendivia 
 Oramorph 
 Oxicodona sandoz 
 Cloruro morfina 
 Zomorph 
 Breakyl 
 Matrifen 
 Fentanilo 
 Morfina clorhide 
 Dolantina 
 
 I am not currently taking, and nor have I ever tried, any of these drugs 
Q6b 
Which if these drugs do you rely on the most for pain relief (i.e. select the one you use most routinely to help 
manage your pain)? Select one drug from the list 
 
In the rest of the survey, when we mention opioid drugs we would like you to think of only the ones on this list 
and not any others. 
Q7 
Now I would like to ask you a few questions about your digestive health e.g., pain or discomfort related to your 
stomach or bowels. Let us start with your bowel movements.   
 
 Over the past ONE week, on how many days did you have bowel movements? 
 Every day 
 Almost every day (5-6 days) 
 Every other day (3-4 days) 
 2 days over the past 7 days 
 1 day over the past 7 days 
 I did not move my bowels at all over the past 
      7 days 
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Q8 
To what extent is moving your bowels bothersome for you e.g. because you cannot use the toilet as often as you 
would like, or because you experience pain, discomfort, or difficulties with daily activities? 
 Not at all 
 A little 
 A moderate amount 
 Quite a lot 
 A great deal 
Q9a 
Given below is a list of treatments that people typically take to help with their bowel movements.  
 
 Could you please select the ones that you are currently taking 
 I do not take any treatments to help with my bowel movements 
 Bisacodyl 
 Capsuvac 
 Celevac 
 Co-Danthramer 
 Co-Danthrusate 
 Constella 
 Dioctyl 
 Docusol 
 Duclcolax Perles 
 Dulcolax 
 Duphalac 
 Galulose 
 Lactuflave 
 Lactugal 
 Lactulose 
 Laevolac 
 Lecicarbon A 
 Lecicarbon C 
 Manevac 
 Micolette 
 Movicol 
 Movicol-half 
 Norgalax 
 Norgalax Micro-enema 
 Phospho-Soda 
 Regulose 
 Resolor 
 Senna 
 Senokot 
 Sodium Picosulfate 
 Strong Co-Danthramer 
 Adulax 
 Belmalax 
 Constella 
 Dulcolax 
 Duphalac 
 EvacuolEnema Casen 
 Fave de fucaEvacuol 
 GutalaxFave de fuca 
 LactulosaGutalax 
 LactuloseLactulosa 
 LaxonolLactulose 
 MicrolaxLaxonol 
 MovicolMicrolax 
 PicosalaxMovicol 
 PlantabenPicosalax 
 ResolorPlantaben 
 SennaResolor 
 Senna 
 Agiolax 
 Arkogelules Sene 
 Auxitrans 
 Bebegel 
 Boldoflorine 
 Chlorumacene 
 Dragees 
 Dulcolax 
 Duphalac 
Q9b 
Which of these treatments do you rely on the most to help with your bowel movements (i.e. select the one you 
use most routinely to help with bowel movements)? Select one drug from the list 
Q10 
How dissatisfied or satisfied are you with ___________________ in terms of how much it helps you to improve 
your bowel movements (e.g., increasing regularity, relieving pain or discomfort) ? 
 Very dissatisfied 
 Somewhat dissatisfied 
 Neither dissatisfied or satisfied 
 Somewhat satisfied 
 Very satisfied 
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Q11 
How dissatisfied or satisfied are you with ___________________ in terms of how convenient it is to use (e.g. it was 
easy to prepare, it had no inconvenient side effects)? 
 Very dissatisfied 
 Somewhat dissatisfied 
 Neither dissatisfied or satisfied 
 Somewhat satisfied 
 Very satisfied 
 
Thank you very much for taking the time to look at this short survey about chronic pain and your health in 
general. The aim of the study is to learn about your health, and not to advertise or promote any particular 
treatments or services. The survey is being conducted by Insight Dojo, an independent research company based 
in the UK, and is being sponsored by a pharmaceutical company. Because the questions relate to your health, 
some of them are of a sensitive nature. The research is entirely confidential, meaning that no individual data will 
be passed on to the pharmaceutical company that is sponsoring the study. The company  will see only the 
combined results across all respondents (or large groups of respondents). 
 
By entering the survey, you consent to the collection of your data for research purposes. All data will be 
processed in adherence to the Market Research Society's Code of Conduct and the Data Protection Act 1998.  
 
Now we will ask you further details about your chronic pain, opioid drugs and digestive health. Often, we will 
use the term constipation to describe difficulties in bowel movements such as irregular movements, discomfort 
or pain. 
 
Q12a 
The table below lists the different preparations (e.g. tablets, oral liquids, injections) that are available for the 
opioid drugs that you are currently taking.Please indicate which preparation of the drug(s) you currently take. 
 Diamorphine INJECTION 
 Diamorphine TABLETS/ CAPSULES 
 Diamorphine POWDER 
 Morphine sulphate ORAL LIQUID 
 Morphine sulphate INJECTION 
 MST continus TABLETS/ CAPSULES 
 MST continus POWDER 
 Oxycodone TABLETS/ CAPSULES 
 Oxycodone ORAL LIQUID 
 Oxynorm TABLETS/ CAPSULES 
 Oxynorm ORAL LIQUID 
 Oxynorm INJECTION 
 Palexia TABLETS/ CAPSULES Palexia SR prolonged-release tablets 
 Palexia TABLETS/ CAPSULES Not prolonged release 
 Palladone TABLETS/ CAPSULES Palladone SR prolonged-release capsules 
 Palladone TABLETS/ CAPSULES Capsules 
 Physeptone ORAL LIQUID 
 Physeptone INJECTION 
 Physeptone TABLETS/ CAPSULES 
 Oxynorm COMPRIMIDOS/CÁPSULAS 
 Oxynorm LÍQUIDO ORAL 
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 Metasedin COMPRIMIDOS/CÁPSULAS 
 Metasedin LÍQUIDO ORAL 
 Methadone AP HP COMPRIMÉS/GÉLULES 
 Methadone AP HP LIQUIDE ORAL 
 Oramorph LIQUIDE ORAL 
 Oramorph LIQUIDE ORAL 
 Oramorph ORAL LIQUID 
 Oramorph ORAL LIQUID 
 Metadone Molteni ORAL LIQUID 
 Metadone Molteni ORAL LIQUID 
 Temgesic INJECTION 
 Temgesic TABLETS/ CAPSULES 
 Morphin TABLETS/ CAPSULES 
 Morphin INJECTION 
 Palladon TABLETS/ CAPSULES prolonged-release capsules 
 Palladon TABLETS/ CAPSULES not prolonged-release capsules 
 Palladon INJECTION 
 MST TABLETS/ CAPSULES 
 MST POWDER 
 M-stada TABLETS/ CAPSULES 
 M-stada INJECTION 
 Temgesic TABLETS/ CAPSULES sublingual tablets 
 Temgesic INJECTION 
 Buprenorphine TABLETS/ CAPSULES sublingual tablets 
 Buprenorphine TRANSDERMAL (SKIN) PATCH 
 Oramorph ORAL LIQUID Pre-measured vial, ampoule or pot of liquid 
 Oramorph LIQUID DROPS 
Q12b 
The table below lists the different strengths that are available for your current opioid drugs. Please think about the 
most recent day when you had opioid drugs to relieve pain. Which of these drugs did you have? How many of each 
of the listed items did you take that day? 
 Abstral TABLETS/ CAPSULES Sublingual tablets 100 micrograms 
 Abstral TABLETS/ CAPSULES Sublingual tablets 200 micrograms 
 Abstral TABLETS/ CAPSULES Sublingual tablets 300 micrograms 
 Abstral TABLETS/ CAPSULES Sublingual tablets 400 micrograms 
 Abstral TABLETS/ CAPSULES Sublingual tablets 600 micrograms 
 Abstral TABLETS/ CAPSULES Sublingual tablets 800 micrograms 
 Actiq OTHER Lozenges 200 micrograms 
 Actiq OTHER Lozenges 400 micrograms 
 Actiq OTHER Lozenges 600 micrograms 
 Actiq OTHER Lozenges 800 micrograms 
 Actiq OTHER Lozenges 1200 micrograms 
 Actiq OTHER Lozenges 1600 micrograms 
 Butrans TRANSDERMAL (SKIN) PATCH 5 micrograms/hour 
 Butrans TRANSDERMAL (SKIN) PATCH 10 micrograms/hour 
 Butrans TRANSDERMAL (SKIN) PATCH 15 micrograms/hour 
 Butrans TRANSDERMAL (SKIN) PATCH 20 micrograms/hour 
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 Diamorphine INJECTION 5mg 
 Diamorphine INJECTION 10mg 
 Diamorphine INJECTION 30mg 
 Diamorphine INJECTION 100mg 
 Diamorphine INJECTION 500mg 
 Diamorphine TABLETS/ CAPSULES 10mg 
 Diamorphine POWDER 5mg 
 Diamorphine POWDER 10mg 
 Diamorphine POWDER 30mg 
 Diamorphine POWDER 100mg 
 Diamorphine POWDER 500mg 
 Durogesic Dtrans TRANSDERMAL (SKIN) PATCH 12 micrograms/hour 
 Durogesic Dtrans TRANSDERMAL (SKIN) PATCH 25 micrograms/hour 
 Durogesic Dtrans TRANSDERMAL (SKIN) PATCH 50 micrograms/hour 
 Durogesic Dtrans TRANSDERMAL (SKIN) PATCH 75 micrograms/hour 
 Durogesic Dtrans TRANSDERMAL (SKIN) PATCH 100 micrograms/hour 
 Fencino TRANSDERMAL (SKIN) PATCH 12 micrograms/hour 
 Fencino TRANSDERMAL (SKIN) PATCH 25 micrograms/hour 
 Fencino TRANSDERMAL (SKIN) PATCH 50 micrograms/hour 
 Fencino TRANSDERMAL (SKIN) PATCH 75 micrograms/hour 
 
Note: if you currently take an oral liquid, or use a nasal spray, we will ask about these separately. 
Q12c 
Roughly how many sprays did you take on that day for each of the nasal sprays you took? 
Pecfent OTRO FORMATO  Aerosol nasal 100 microgramos/ dose  
Pecfent OTRO FORMATO  Aerosol nasal 400 microgramos/ dose  
Instanyl OTRO FORMATO Aerosol nasal 50 microgramos/dose  
Instanyl OTRO FORMATO Aerosol nasal 100 microgramos/dose  
Instanyl OTRO FORMATO Aerosol nasal 200 microgramos/dose  
Instanyl AUTRE Spray nasal 50 microgrammess/dose  
Instanyl AUTRE Spray nasal 100 microgrammess/dose  
Instanyl AUTRE Spray nasal 200 microgrammess/dose  
Pecfent AUTRE Spray nasal 100microgrammes/ dose  
Pecfent AUTRE Spray nasal 400microgrammes/ dose  
Pecfent ALTRO Spray nasale 100 microgrammi/ dose  
Pecfent ALTRO Spray nasale 400 microgrammi/ dose  
Instanyl ALTRO Spray nasale 50 microgrammi/dose  
Instanyl ALTRO Spray nasale 100 microgrammi/dose  
Instanyl ALTRO Spray nasale 200 microgrammi/dose  
Instanyl NASAL SPRAY  50 Mikrogramms/dose  
Instanyl NASAL SPRAY  100 Mikrogramms/dose  
Instanyl NASAL SPRAY  200 Mikrogramms/dose  
Pecfent NASAL SPRAY  100 Mikrogramm/dose  
Pecfent NASAL SPRAY  400 Mikrogramm/ dose  
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Q12d 
Roughly how many mililitres did you take on that day for each of the oral liquids you took? 
Please write your answer in milliletres (ml) 
Methadone ORAL LIQUID 1mg/1ml 
Methadone ORAL LIQUID 10mg/1ml 
Methadone ORAL LIQUID 20mg/1ml 
Morphine sulphate ORAL LIQUID 10mg/5ml 
Morphine sulphate ORAL LIQUID 20mg/ml 
Oramorph ORAL LIQUID 10mg/5ml 
Oramorph ORAL LIQUID 20mg/1ml 
Oxycodone ORAL LIQUID 10mg/ml 
Oxycodone ORAL LIQUID 5mg/5ml 
Oxynorm ORAL LIQUID 10mg/ml 
Oxynorm ORAL LIQUID 5mg5/ml 
Physeptone ORAL LIQUID 1mg/1ml 
Oxynorm LÍQUIDO ORAL Botella de líquido 10mg/ml 
Oxynorm LÍQUIDO ORAL Botella de líquido 5mg/5ml 
Oramorph LÍQUIDO ORAL Botella de líquido 2mg/ml 
Oramorph LÍQUIDO ORAL Botella de líquido 6mg/ml 
Oramorph LÍQUIDO ORAL Botella de líquido 20mg/ml 
Methadone AP HP LIQUIDE ORAL Pré-mesurée flacon, ampoule ou un pot de liquide 5mg/3.75ml 
Methadone AP HP LIQUIDE ORAL Pré-mesurée flacon, ampoule ou un pot de liquide 1.33mg/ml 
Oramorph LIQUIDE ORAL drops oral 20mg/1ml 
Q12e 
So, your total dose of each drug was ___________________ 
 Yes, the doses are correct (continue to the next question) 
 No, one or more of the doses are incorrect (re-enter the correct amount) 
Q12f 
You indicated that the dose for one or more of your medications was incorrect. Please enter the correct dose, 
together with the unit of measurement (milligrams, micrograms, milliletres), if you know it, in the box next to the 
relevant drug. 
Note, if all of the doses are, in fact, correct, select 'Next' 
Q13 
Now, I would like you to think back to when you were first prescribed opioid drugs. When I say opioid drugs, 
I mean the drugs we have shown you before. 
Click here for a reminder. 
 
Roughly, how long ago were you first prescribed opioid drugs? 
Please choose one option only 
 In the last 3 months 
 More than 3 months, but less than one year ago 
 1 year or more, but less than 3 years 
 3 years or more, but less than 5 years 
 5 years or more, but less than 10 years 
 10 years or more 
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Q14a 
Thinking back to the time before you started taking opioid medications: 
 
How was your experience of constipation then? 
Please choose one option only 
 It was much better 
 It was slightly better 
 It was the same 
 It was slightly worse 
 It was much worse 
Q14b 
Could you roughly tell us how many days in a week did you have bowel movements before you started taking 
opioid medications? 
 Every day 
 Almost every day (5-6 days) 
 Every other day (3-4 days) 
 2 days per week 
 1 day per week or less 
Q15 
Thinking about the first time you were prescribed an opioid drug, which of the following medical professionals first 
prescribed an opioid drug to you? 
Please choose one option only 
 GP 
 Anaesthetist 
 Neurologist 
 Rheumatologist 
 Psychiatrist  
 Orthopaedist 
 Oncologist 
 Nurse specialist 
 Pain specialist doctor 
 Pharmacist 
 Internist 
 Other 
Q16 
Now I would like you to think back to the conversation that you had with the doctor. Which, if any, of the following 
did your doctor (or other medical professional) do when prescribing the opioid drug to you for the first time? 
Select all that apply 
 Warned me about drowsiness as a potential side effect of the opioid drug 
 Warned me about nausea and/or vomiting as a potential side effect of the opioid drug 
 Warned me about constipation as a potential side effect of the opioid drug 
 Suggested that I change my diet or lifestyle (e.g. by eating more fibre or exercising more often) to avoid 
constipation 
 Prescribed me a laxative drug to avoid constipation 
 Did none of these 
 I don’t remember 
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Q17 
Which of the followinfag medical professionals is primarily responsible for repeat prescription of your opioid 
medications? 
Please select one option only 
 GP 
 Anaesthetist 
 Neurologist 
 Rheumatologist 
 Psychiatrist 
 Orthopaedist 
 Oncologist 
 Nurse specialist 
 Pain specialist doctor 
 Pharmacist 
 Internist 
 Other 
Q18 
Whom do you look to for help with managing constipation? 
Select all that apply 
 GP 
 Anaesthetist 
 Neurologist 
 Rheumatologist 
 Psychiatrist 
 Orthopaedist 
 Oncologist 
 Nurse specialist 
 Pain specialist doctor 
 Pharmacist 
 Internist 
 Members of my family 
 My friends 
 Other constipation sufferers 
 I do not look for help, 
 I manage constipation myself 
 Other 
Q19a 
Thinking about your opioid drug usage over the years:  
 
How has your opioid drug usage changed, if at all? 
 It has increased a lot 
 It has increased slightly 
 It has been the same 
 It has decreased slightly 
 it has decreased a lot 
Q19b 
Thinking back to the last time when there was an increase in your total dosage of opioid drugs, what was the effect 
on your constipation? 
 My constipation became much better 
 My constipation became slightly better 
 My constipation remained the same 
 My constipation became slightly worse 
 My constipation became much worse 
Q20 
Thinking about the future, how do you expect your opioid drug usage to change? 
 I expect it to increase a lot 
 I expect it to increase slightly 
 I expect it to be the same as now 
 I expect it to decrease slightly 
 I expect it to decrease a lot 
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Q21a 
Thinking about your opioid drug usage over the years: 
Has there been a change in the specific opioid drug you were taking? 
 Yes  No 
Q21b 
The last time there was a change in the specific opioid drug(s) that you were taking, what was the effect on 
constipation? 
 My constipation became much better 
 My constipation became slightly better 
 My constipation remained the same 
 My constipation became slightly worse 
 My constipation became much worse 
 
This section asks about your experience of constipation, and measures that you have taken to help with this. 
Q22 
How much do you disagree or agree that the following caused you discomfort over the past TWO weeks? 
 
Disagree 
strongly 
Disagree 
quite a lot 
Disagree 
a little 
Neither 
agree nor 
disagree 
Agree 
a little 
Agree 
quite a 
lot Agree strongly 
Incomplete bowel 
movement, like you 
didn’t “empty” yourself 
       
Passing of stools that 
were too hard or lumpy 
       
Straining to try 
to pass stools 
       
Sensation of a blockage 
or obstruction in your 
bowel movements 
       
Bloating in 
your abdomen 
       
Stomach cramps        
Rectal burning 
(during or after a 
bowel movement) 
       
Hemorrhoids (also 
known as ‘piles’) 
       
Other 
(non-hemorrhoidal) 
rectal bleeding 
       
Nausea        
Vomiting        
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Q23 
Over the past TWO weeks, to what extent did your constipation symptoms cause you to feel each of the following: 
 1 
Not at 
all 2 3 
4 
A moderate 
amount 5 6 
7 
A great 
deal 
Disgusted        
Frustrated        
Helpless        
Depressed        
Dependant and “not free”        
Obsessed i.e. not being able to get it 
out of your mind 
       
Anxious or worried        
Q24 
 1 
Not at 
all 2 3 
4 
A moderate 
amount 5 6 
7 
A great 
deal 
Spend excessive time in the bathroom        
Have difficulty socialising        
Have difficulty working (including both paid work 
and household chores) 
       
Have difficulty pursuing hobbies        
Have difficulty being intimate with others        
Have difficulty following your normal routine        
Have difficulty taking your opioid drugs as normal        
Q25a 
Given below are a number of approaches that people use to relieve constipation. 
 
Which of these approaches do you use on a regular basis, if any? There are no right or wrong answers. 
 Used a single laxative treatment on its own 
 Combined multiple laxative treatments 
 Rotated among different opioid drug treatments 
 Decreased the dose or frequency of your opioid drug treatment(s) 
 Skipped a dose of your opioid drug treatment(s) 
 Skipped several doses of your opioid drug treatment(s) 
 Used an alternative (non opioid) painkiller 
 Used manual methods (e.g. using your fingers) to support evacuation 
 Drank more water, juice, or other fluids 
 Eaten less, or been careful about what you ate 
 Obtained additional fibre through your diet (e.g. by eating more fruit, vegetables, or cereal)? 
 Taken a fibre supplement product (e.g. Fybogel, or a psyllium or methywarnlcellulose product) 
 Exercised more often 
 Had colonic hydrotherapy (also known as 'irrigation') 
 Used a suppository or enema (a solid or liquid preparation inserted into the rectum) 
 Used relaxation techniques (e.g. deep breathing, meditation) 
 An approach I devised myself to deal with constipation 
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Q25b 
Now think back to the last time you experienced severe constipation. Which of the following approaches did you 
use to manage your constipation then? 
 Used a single laxative treatment on its own 
 Combined multiple laxative treatments 
 Rotated among different opioid drug treatments 
 Decreased the dose or frequency of your opioid drug treatment(s) 
 Skipped a dose of your opioid drug treatment(s) 
 Skipped several doses of your opioid drug treatment(s) 
 Used an altenative (non opioid) painkiller 
 Used manual methods (e.g. using your fingers) to support evacuation 
 Drank more water, juice, or other fluids 
 Eaten less, or been careful about what you ate 
 Obtained additional fibre through your diet (e.g. by eating more fruit, vegetables, or cereal)? 
 Taken a fibre supplement product (e.g. Fybogel, or a psyllium or methylcellulose product) 
 Exercised more often 
 Had colonic hydrotherapy (also known as 'irrigation') 
 Used a suppository or enema (a solid or liquid preparation inserted into the rectum) 
 Used relaxation techniques (e.g. deep breathing, meditation) 
 An approach I devised myself to deal with constipation 
 
This section asks for further information about the constipation treatments (laxative drugs) that you currently 
use most often. 
Q26 
To what extent do you disagree or agree with the following statements regarding the laxative drug 
_____________? 
 
Disagree 
strongly 
Disagree 
quite a lot 
Disagree 
a little 
Neither 
agree nor 
disagree 
Agree 
a little 
Agree 
quite a 
lot Agree strongly 
Taking everything into 
consideration, I am very 
satisfied with the 
laxative drug 
       
It allows me to move my 
bowels more easily 
       
It relieves any pain I 
experience in moving 
my bowels 
       
It has no inconvenient or 
problematic side effects 
       
It is easy to prepare 
and administer 
       
It is discreet and 
easy to carry around 
       
It works rapidly to 
control my constipation 
       
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Disagree 
strongly 
Disagree 
quite a lot 
Disagree 
a little 
Neither 
agree nor 
disagree 
Agree 
a little 
Agree 
quite a 
lot Agree strongly 
symptoms 
It is affordable        
It works predictably        
It represents good value 
for money 
       
It is available on the 
National Health Service – 
or the cost is reimbursed 
       
 
This section asks about your attitudes on a variety of issues relating to opioid drugs, constipation, and your 
health in general. 
Q27a 
Given below are a number of statements related to your attitudes and beliefs about pain and opioids. There are no 
right or wrong answers. We are interested only in your opinions. 
 
To what extent do you disagree or agree with the following statements? 
 
Disagree 
strongly 
Disagree 
quite a lot 
Disagree 
a little 
Neither 
agree nor 
disagree 
Agree 
a little 
Agree 
quite a 
lot 
Agree 
strongly 
I feel really overwhelmed by 
my pain 
       
I am the type of person who 
likes to get on with my life 
despite my pain 
       
I would rather suffer a little 
from pain rather than take 
pain medications 
       
My opioid drugs have allowed 
me to live a fuller life 
       
I find it difficult to cope 
without my opioid drugs 
       
I don’t like my opioid drugs 
and have them only if it is 
absolutely necessary 
       
I believe my health will 
improve and I will be able to 
discontinue my opioid drugs 
in the future 
       
I often feel guilty when I take 
opioid drugs 
       
I think doctors must be more 
careful than they are while 
prescribing opioid drugs 
       
I feel that pharmaceutical 
companies that manufacture 
       
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Disagree 
strongly 
Disagree 
quite a lot 
Disagree 
a little 
Neither 
agree nor 
disagree 
Agree 
a little 
Agree 
quite a 
lot 
Agree 
strongly 
opioid drugs are really 
improving the lives of patients 
My experience of pain has 
helped me realise what is 
truly important 
       
Because of my pain I no 
longer take people or things 
for granted 
       
My experience of pain has 
helped me appreciate the 
value of living everyday to the 
full 
       
My experience of pain has 
made me question who I am 
as a person 
       
I wish I could keep using my 
opioid pain medication 
without having the 
constipation side effects 
       
While opioid drugs relieve 
pain, the side effects make it 
difficult to do daily activities 
       
I hate having to balance 
getting pain relief with 
constipation side effects 
       
I am unable to control my 
pain properly because of the 
constipation side effects 
       
I have a group of supportive 
people who make it easier to 
cope with pain 
       
People suffering from pain 
and other health conditions 
frequently reach out to me 
for support 
       
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Q28 
Given below are a number of statements related to your attitudes and beliefs about constipation, stomach health, 
and its impact on your life. There are no right or wrong answers. We are interested only in your opinions. 
 
To what extent do you disagree or agree with the following statements? 
 
Disagree 
strongly 
Disagree 
quite a lot 
Disagree 
a little 
Neither 
agree nor 
disagree 
Agree 
a little 
Agree 
quite a 
lot 
Agree 
strongly 
I feel upset if I cannot move 
my bowels every day 
       
My constipation is awful 
and overwhelms me 
       
At the back of my mind, 
I’m always thinking 
of constipation 
       
After pain, constipation 
is one of my most 
bothersome problems 
       
I often cut down my 
opioid medication to 
relieve my constipation 
       
I would prefer not to reduce 
my opioid medication to 
relieve my constipation 
       
I often worry that my bowels 
will lose their ability to 
function normally 
       
Constipation prevents me 
from doing things that I 
really want 
       
I take extreme measures to 
get relief from constipation 
that might not be good for 
me in other ways 
       
Often constipation gets so 
bad, that I have to combine 
many different treatments 
       
It bothers me that I spend so 
much time in the bathroom 
because of my constipation 
       
Often I am afraid that I will 
fall in the bathroom and 
injure myself 
       
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Q29a 
Given below are a number of statements related to your attitudes and beliefs about treatments that you use for 
constipation. There are no right or wrong answers. We are interested only in your opinions. 
 
To what extent do you disagree or agree with the following statements? 
 
Disagree 
strongly 
Disagree 
quite a 
lot 
Disagree 
quite 
little 
Neither 
agree nor 
disagree 
Agree 
a little 
Agree 
quite a 
lot 
Agree 
strongly 
I would much prefer to take 
natural (non pharmaceutical) 
treatments for my constipation 
       
I would much prefer to change 
my diet, or some other aspect of 
my lifestyle, rather than taking 
pharmaceutical treatments for 
constipation 
       
I would much rather take a 
constipation treatment as and 
when the need arises rather 
than take it continuously 
       
I would much prefer a 
constipation treatment that 
I could use continuously, over 
the long term, as opposed to 
one that could only be taken 
when required 
       
For me, it is very important 
that a constipation treatment 
works fast 
       
For me, it is very important that 
a constipation treatment works 
predictably and not at random 
       
For me, it is very important that 
a constipation treatment can be 
taken at any time of the day 
       
For me, it is very important that 
I can take my constipation 
treatment with or without food 
       
For me, it is very important that 
my constipation treatment does 
not affect the pain relief that 
I get from my opioid drugs 
       
For me, it is very important that 
my constipation treatment does 
not affect the way that I take my 
opioid drugs (e.g. the timing, the 
dosage of my opioids) 
       
For me, it is very important that 
a constipation treatment has no 
bad side effects 
       
If I were to try a new treatment        
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Disagree 
strongly 
Disagree 
quite a 
lot 
Disagree 
quite 
little 
Neither 
agree nor 
disagree 
Agree 
a little 
Agree 
quite a 
lot 
Agree 
strongly 
for constipation, I would rather 
not have to immediately give up 
using laxative drugs 
Having to prepare laxatives is 
not inconvenient for me 
       
I would much prefer to take an 
oral pill rather than a liquid 
treatment to help manage my 
constipation 
       
I am constantly on the look out 
for new treatments for 
constipation 
       
Q30 
Given below are a number of statements related to your attitudes and beliefs about the way you manage your 
health. There are no right or wrong answers. We are interested only in your opinions. To what extent do you 
disagree or agree with the following statements? 
 
 
Disagree 
strongly 
Disagree 
quite a lot 
Disagree 
a little 
Neither 
agree nor 
disagree 
Agree 
a little 
Agree 
quite a 
lot 
Agree 
strongly 
I consider myself more 
knowledgeable than most 
about my health conditions 
       
I do my own research 
regarding my health 
condition(s) and treatments 
       
I strictly follow the regimens 
that my doctor(s) prescribe 
       
I think it is very important to 
adapt one’s medication 
regime oneself rather than 
follow the doctor’s instruction 
       
I would have appreciated 
additional help from my 
doctor or medical professional 
regarding constipation 
       
I like to deal with constipation 
on my own rather than speak 
to the doctor about it 
       
I wish my doctor would 
spend more time speaking 
to me about my constipation 
problems 
       
I would rather not discuss my 
constipation with my doctors 
       
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This section asks about your personal characteristics and circumstances, and your health. 
Q34 
Are you male or female? 
 Male  Female 
Q35 
Please indicate your employment status: 
 Working full-time 
 Working part-time 
 Self-employed 
 Unemployed 
 Student or in full-time training 
 Retired 
 Semi retired 
Q36 
To what extent does your work require extensive physical activity (e.g. extensive walking, travelling)? 
 1 
Not at all 2 3 
4 
A moderate amount 5 6 
7 
A great deal 
        
Q36b 
How long, on average, does your regular commute to work take? 
 Less than 15 minutes 
 15 minutes but less than 30 minutes 
 30 minutes or more but less than one hour 
 One hour or more but less than 90 minutes 
 90 minutes or more but less than two hours 
 Two hours or more 
Q37 
What is your total household income (£)? Your household income includes the total income of all of the people 
who you live with. 
 0-9,999 
 10,000-24,999 
 25,000-39,999 
 40,000-54,999 
 55,000-69,999 
 70,000-84,999 
 85,000-99,999 
 100,000 or more 
 Prefer not to say 
Q38 
Which of the following best represents your relationship status? 
 Single (i.e. not currently in a relationship rather 
than legal status) 
 In a relationship 
 Civil Partnership 
 Married 
 Separated 
 Divorced 
 Widowed 
 Prefer not to say 
Q39 
Do you have any children? 
 Yes  No 
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Q40 
Are your children still at home or independent? 
 Under 18 and still at home 
 Adult children still at home 
 Mix of independent and still at home 
 Independent 
Q41 
In a typical week, how many hours per day do you spend reading/listening/watching the following...? 
 Not at all Less than an hour 1-2 hours 3-5 hours 6-10 hours More than 10 hours 
TV       
Radio       
Magazines       
Newspapers       
Internet       
Q41a 
At what time of day do you typically watch TV? 
Select all that apply 
 Morning 
 Afternoon 
 Evening/ night 
Q41b 
How do you typically watch TV? 
Select all that apply 
 Live (as it happens) 
 Catch-up (via a set top Box) 
 Online via TV channel website 
Q41c 
What technology do you typically use to watch TV? 
Select all that apply 
 A regular TV set 
 A laptop computer 
 An ipad or tablet 
 A desktop computer 
 A smartphone 
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Q41d 
Which of the following newspapers do you read on a regular basis (e.g. at least once per week)? 
Select all that apply. 
 The Guardian 
 The Times 
 The Daily Telegraph 
 The Financial Times 
 The i (concise newspaper) 
 Metro 
 The Daily Mail 
 The Daily Express 
 The Sun 
 The Daily Mirror 
 The Daily Star 
 The Daily Record 
 Evening Standard 
 Other (please specify)____________ 
Q42 
Which of the following social networking platforms and sites do you use on a regular basis? 
Select all that apply 
 Facebook 
 Copains d’Avant 
 Tuenti 
 LinkedIn 
 Viadeo 
 XING 
 Twitter 
 Instagram 
 WhatsApp 
 Google+ 
 Snapchat 
 Other (please specify)____________ 
 None of these 
Q43 
Where do you get information and advice regarding health issues/concerns? 
Select all that apply 
 Healthcare professionals (including doctors 
and nurses) 
 Your partner 
 Other family member(s) 
 My friend(s) 
 Leaflets in my doctor’s surgery 
 Library / books / literature 
 Newspaper/ Magazines 
 Television 
 Radio 
 Online search engines like Google 
 Online health forums 
 Online blogs 
 Other online sources 
 None of the these 
Q44 
Please indicate which, if any, of the following conditions you have? 
Select as many as apply 
 Diabetes 
 Diverticulosis 
 Thyroid disturbance 
 Stroke 
 Multiple Sclerosis 
 Spinal injury 
 Anxiety 
 Depression 
 Heart Disease 
 Osteoporosis 
 Arthritis/ Rheumatism 
 Respiratory diseases (e.g. asthma, COPD, 
      emphysema, chronic bronchitis) 
 Cancer 
 None of the above 
 Prefer not to say 
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Q45 
Do you have a full-time carer? 
 Yes  No 
Q46 
To what extent does your carer help you to manage your constipation? 
 1 
Not at all 2 3 
4 
A moderate amount 5 6 
7 
A great deal 
        
Q47 
To what extent do you see yourself as: 
 1 
Not at all 2 3 
4 
A moderate amount 5 6 
7 
A great deal 
Extraverted, enthusiastic        
Critical, quarrelsome        
Dependable, self-disciplined        
Anxious, easily upset        
Open to new experiences, complex        
Reserved, quiet        
Sympathetic, warm        
Disorganized, careless        
Calm, emotionally stable        
Conventional, uncreative        
Q48 
Which of the following options best describes the effect of your chronic pain on your daily life? 
Select one option only. 
 I am fully active just like I was before the onset of chronic pain 
 I’m restricted in physically strenuous activity but can walk around, and able to carry out work of a light or  
      sedentary nature, e.g., light house work, office work 
 I can walk around, and am capable of taking care of myself. I am unable to carry out any work activities, and be  
      up and about more than 50% of waking hours 
 I am completely disabled. I cannot look after myself and I am confined to a bed or chair all of the time. 
Q49 
Which of the following activities do you do to help distract you from your pain, or to cope better with it? 
Select all that apply. 
 Watching TV programmes 
 Meeting friends and family socially 
 Connecting with friends on social networks (e.g., Whatsapp, Facebook) 
 Connecting with other people who are suffering from similar health conditions either in person or through  
      social networks 
 Practising an art (e.g., drawing, photography, singing, playing and instrument) 
 Playing a sport (football, tennis, etc.) 
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 Playing an indoor game 
 Watching movies 
 Watching sports events 
 Do research and learn new things (e.g., learn a new language, take an online course) 
 Doing cardiovascular exercises (running, aerobics, etc.) 
 Doing mind-body exercises (e.g., Yoga,  Tai-Chi, Alexander Technique) 
 Physiotherapy 
 Going for walks 
 Spending time with nature 
 Going to watch music events 
 Going to the museum 
 Doing shopping 
 Writing about my experience (e.g., writing a blog or a diary) 
 Meeting a counsellor, a mentor or a coach 
 None of these 
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Weak-opioid use questionnaire 
Are you …  
1. Male 2. Female 
 
How old are you? 
 
Age 
1. 16 – 24 
2. 25 – 34 
3. 35 – 44 
4. 45 – 54 
5. 55 – 64 
6. 65+ 
 
In which region do you live? 
IF Country=1 (UK) 
1. North East 
2. North West  
3. Yorkshire & the Humberside 
4. East Midlands 
5. West Midlands 
6. East of England 
7. London – inside M25  
8. South East 
9. South West  
10. Wales 
11. Scotland 
12. Northern Ireland 
13. Channel Islands 
 
IF Country=5 (GERMANY) 
1 Baden-Württemberg 
2 Bayern 
3 Berlin 
4 Brandenburg 
5 Bremen 
6 Hamburg 
7 Hessen 
8 Mecklenburg-Vorpommern 
9 Niedersachsen 
10 Nordrhein-Westfalen 
11 Rheinland-Pfalz 
12 Saarland 
13 Sachsen 
14 Sachsen-Anhalt 
15 Schleswig-Holstein 
16 Thüringen 
 
IF Country=6 (SPAIN) 
1 Navarra 
2 Aragón 
3 Cataluña 
4 Baleares, Islas 
5 Com. Valenciana 
6 Reg.Murcia 
7 Andalucía 
8 Canarias, Islas 
9 Melilla 
10 Extemadura 
11 Ceuta 
12 Com. Madrid 
13 Cantabria 
14 Asturias 
15 Rioja, La 
16 Euskadi 
17 Galicia 
18 Castilla La Mancha 
19 Castilla y León 
 
Q1 
Do you, or any members of your immediate family, work for any of the following industries? 
 
1= Advertising 
2 =Market research 
3= PR or marketing industry 
4= Healthcare or medical industry 
5= Manufacture or sale of pharmaceutical products 
99= None of these 
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For the next question we’d like to understand a bit about your general health. 
 
Q3a 
Which, if any, of these do you ever suffer from?  
 
1 
Any type of pain (please consider all pains from something mild, like a headache, to something more 
chronic, such as pain caused by arthiritus or cancer) 
2 Insomnia 
3 Problems with your sight 
4 Vertigo/dizziness 
5 Problems with your digestive system, such as IBS 
99 None of these 
 
Q3 
Which, if any, of the following chronic pain conditions do you suffer from?  
 
1=Chronic back pain 
2=Rheumatoid Arthritis 
3=Osteoarthritis 
4=Psoriatic Arthritis  
5=Joint pain  
6=Fibromyalgia 
7=Neuropathic pain relating 
     to diabetes 
8=Neuropathic pain not relating  
     to diabetes 
9=Post herpetic neuralgia 
10=Non Herpetic neuralgia 
11=Migraine 
12=Headache  
13=Pain relating to cancer 
14=Shoulder pain/ stiffness  
15=Neck pain  
16=Hip/ pelvic pain  
17=Carpal tunnel syndrome  
18=Dental pain  
19=Tendonitis  
20=Broken bones  
21=Menstrual pain 
22=Plantar fasciitis  
23=Sprains or strains  
98=Other pain condition 
96=Prefer not to say 
99=None of these
Q4 
Which of these pain conditions cause you the most severe pain i.e., the one for which you need the 
strongest pain treatment? 
 
Q5 
When did you first begin to experience chronic pain relating to __________? 
1=In the last 3 months 
2=More than 3 months, but less than one year ago 
3=1 year or more, but less than 3 years  
4=3 years or more, but less than 5 years  
5=5 years or more, but less than 10 years  
6=10 years or more  
 
Thanks for your response so far. We would now like to understand a bit more about the pain that you 
experience and the treatments that you use. 
 
Given below is a list of opioid drugs that people take for pain relief.  
 
Could you please select the ones that you are currently taking 
 
Q6a2 
Could you please select the ones that you have tried before, but are not currently taking  
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Q6b 
Which if these drugs do you rely on the most for pain relief (i.e. select the one you use most routinely to 
help manage your pain)? Select one drug from the list 
 
You mentioned above that you are currently taking __________ for pain relief.  Drugs like these are part of 
the opioid family - that is, they are medications derived from opium that help relieve pain. For the rest of 
the study when we refer to ‘opiods’ we would like you to think only about these specific types of medication 
(ie drugs like __________), rather than other treatments you might take. 
 
Q7a 
Taking opioids drugs can have various side-effects. Which of the following, if at all, have you ever suffered 
from? 
 
1 Nausea 
2 Dizziness 
3 Vomiting  
4 Constipation (infrequent bowel movments causing pain/discomfort in your bowels) 
5 Sedation  
6 Physical dependence 
7 Tolerance 
8 Respiratory depression 
99 None of these 
 
Q7 
Now I would like to ask you a few questions about your digestive health e.g., pain or discomfort related to 
your stomach or bowels. Let us start with your bowel movements.  
 
Over the past ONE week, on how many days did you have bowel movements? 
1=Every day 
2=Almost every day (5-6 days) 
3=Every other day (3-4 days) 
4=2 days over the past 7 days 
5=1 day over the past 7 days 
6= I did not move my bowels at all over the past 7 days 
 
Q8 
To what extent is moving your bowels bothersome for you e.g. because you cannot use the toilet as often as 
you would like, or because you experience pain, discomfort, or difficulties with daily activities? 
 
1=Not at all 
2=A little 
3=A moderate amount 
4=Quite a lot 
5=A great deal 
 
Q8b  
Which of these have you ever done to help with infrequent/painful/difficult bowel movements? 
 
1 Taken laxatives  
2 Made changes to your diet (eg introducing more fibre)  
3 Increased the amont of caffeine you drink  
4 Made other changes to your lifestyle, such as increasing the amount of exercise you do 
5 Used a suppository or enema (a solid or liquid preparation inserted into the rectum) 
98 Other (specify) 
99 
None of the above (either have not experienced an issue with bowel movement or haven’t taken any 
of the above courses of action) 
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Q9c 
Are you currently taking laxatives? 
 
1 Yes  
2 No  
 
Q10 
How dissatisfied or satisfied are you with __________ the laxatives you are currently taking in terms of how 
much it helps you to improve your bowel movements (e.g., increasing regularity, relieving pain or 
discomfort)? 
1=Very dissatisfied 
2=Somewhat dissatisfied 
3=Neither dissatisfied or satisfied 
4=Somewhat satisfied 
5=Very satisfied 
 
Thank you very much for taking the time to look at this short survey about chronic pain and your health in 
general. The aim of the study is to learn about your health, and not to advertise or promote any particular 
treatments or services. The survey is being conducted by Insight Dojo, an independent research company 
based in the UK, and is being sponsored by a pharmaceutical company. 
 
The research is entirely confidential, meaning that no individual data will be passed on to the 
pharmaceutical company that is sponsoring the study. 
 
Please be completely honest in your responses. Based on our knowledge of likely patterns within the data, 
it will be easy to detect any dishonest or misleading responses. 
 
Now we will ask you further details about your chronic pain, opioid drugs and digestive health. 
 
Often, we will use the term of constipation to describe difficulties in bowel movements such as irregular 
movements, discomfort or pain.  
 
Q12g 
You mentioned earlier that the treatment you take most often to help with your pain is __________. 
Which form do you currently take this in? 
 
1 A tablet/capsule/caplet (not effervescent or soluable) 
2 An effervescent or soluable tablet/capsule/caplet 
3 A liquid 
4 An injection  
5 A patch  
6 A powder  
98 Other (specify) 
 
Q12h  
How often do you take this treatment? 
 
1 More than once a day  
2 Every day (but only once)  
3 Almost every day  
4 About 3 or 4 times a week 
5 About 1 or 2 times a week  
6 Less than once a week but more than once a month  
7 About once a month  
8 Less often  
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Q13 
Now, I would like you to think back to when you were first prescribed opioid drugs. When I say opioid drugs, 
I mean the drugs we have shown you before. Click here for a reminder. 
 
Roughly, how long ago were you first prescribed opioid drugs? Please choose one option only. 
1=In the last 3 months  
2=More than 3 months, but less  
     than one year ago 
3=1 year or more, but less than 
     3 years  
4=3 years or more, but less than  
     5 years  
5=5 years or more, but less than  
     10 years  
6=10 years or more 
 
Q14a 
Thinking back to the time before you started taking opioid medications: 
 
How was your experience of constipation then? 
1=It was much better  
2=It was slightly better  
3. It was the same  
4. It was slightly worse  
5. It was much worse 
 
Q14b 
Could you roughly tell us how many days in a week did you have bowel movements before you started 
taking opioid medications? 
1=Every day 
2=Almost every day (5-6 days) 
3=Every other day (3-4 days) 
4=2 days per week 
5=1 day per week or less  
 
Q15 
Thinking about the first time you were prescribed an opioid drug, which of the following medical 
professionals first prescribed an opioid drug to you?  
Please choose one option only 
1=GP 
2=Anaesthetist 
3=Neurologist 
4=Rheumatologist 
5=Psychiatrist 
6=Orthopaedist 
7=Oncologist 
8=Nurse specialist 
9=Pain specialist doctor 
10=Pharmacist 
11=Internist 
98=Other 
 
Q16a 
Now I would like you to think back to the conversation that you had with the doctor. Which, if any, of the 
following did your doctor (or other medical professional) do when prescribing the opioid drug to you for the 
first time? 
Select all that apply 
1. Warned me about drowsiness as a potential side effect of the opioid drug 
2. Warned me about nausea and/or vomiting as a potential side effect of the opioid drug 
3. Warned me about constipation as a potential side effect of the opioid drug 
99. Did none of these 
96. I don’t remember 
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Q16b 
And once the doctor had warned you about constipation as a potential side effect, which of the following 
did your doctor suggest?  
Select all that apply 
1. Suggested that I change my diet or lifestyle (e.g. by eating more fibre or exercising more often) to  
 avoid constipation 
2. Prescribed me a laxative drug to avoid constipation 
3. Recommended a specific treatment I could try - such as a laxative - but did not physically write 
 a prescription 
99. Neither of the above – they just warned me that it might be a side effect, but did not make 
 any recommendations 
 
Q16c 
Have you had any subsequent conversations with your doctor (after the first time you were prescribed 
opioids) about constipation?  
 
1 Yes – the doctor has brought it up /asked me about the symptoms on subsequent visits 
2 Yes - I have brought up the topic on subsequent visits  
3 No – we have not spoken about it since 
 
Q16d 
You mentioned that you have never spoken to your doctor about your constipation symptoms.  Why it this?  
Please select all that apply 
 
1 I feel too embarassed to bring the topic up with my doctor  
2 I don’t feel my constipation symptoms are severe enough to warrant a discussion  
3 I don’t want to distract my doctor from helping me with pain relief  
4 I get the advice I need elsewhere (eg by browsing the internet, talking to friends etc)  
5 I don’t think the doctor will be able to help me so I don’t bother bringing it up  
6 I feel confident managing the condition myself 
7 Other (please specify) 
 
Q16e 
Have you subsequently been prescribed a laxative for your opioid induced constipation symptoms? 
 
1 Yes  
2 No   
 
Q17 
Which of the following medical professionals is primarily responsible for repeat prescription of your opioid 
medications? 
Please select one option only 
 
1=GP 
2=Anaesthetist 
3=Neurologist 
4=Rheumatologist 
5=Psychiatrist 
6=Orthopaedist 
7=Oncologist 
8=Nurse specialist 
9=Pain specialist doctor 
10=Pharmacist 
11=Internist 
98=Other 
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Q18 
Whom do you look to for help with managing constipation? 
Select all that apply 
 
1=GP 
2=Anaesthetist 
3=Neurologist 
4=Rheumatologist 
5=Psychiatrist 
6=Orthopaedist 
7=Oncologist 
8=Nurse specialist 
9=Pain specialist doctor 
10=Pharmacist 
11=Internist 
12=Members of my family 
13=My friends 
14=Other constipation sufferers 
15=I do not look for help, 
       I manage constipation myself 
98=Other 
 
Q19a 
Thinking about your opioid drug usage over the years: 
How has your opioid drug usage changed, if at all? 
 
1=It has increased a lot 
2=It has increased slightly 
3=It has been the same 
4=It has decreased slightly 
5=it has decreased a lot 
 
Q19b 
Thinking back to the last time when there was an increase in your total dosage of opioid drugs, what was 
the effect on your constipation? 
 
1=My constipation became much better  
2=My constipation became slightly better  
3=My constipation remained the same 
4=My constipation became slightly worse 
5=My constipation became much worse 
 
Q20 
Thinking about the future, how do you expect your opioid drug usage to change? 
1=I expect it to increase a lot 
2=I expect it to increase slightly 
3=I expect it to be the same as now 
4=I expect it to decrease slightly 
5=I expect it to decrease a lot  
 
Q21a 
Thinking about your opioid drug usage over the years: 
Has there been a change in the specific opioid drug you were taking? 
1=Yes 2=No 
 
Q21b 
The last time there was a change in the opioids, what was the effect on constipation? 
1=My constipation became much better  
2=My constipation became slightly better  
3=My constipation remained the same 
4=My constipation became slightly worse 
5=My constipation became much worse 
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This section asks about your experience of constipation, and measures that you have taken to help with this. 
 
Q22 
How much do you disagree or agree that the following caused you discomfort over the past TWO weeks?  
 
RATING: 
Disagree 
strongly 
Disagree 
quite a lot 
Disagree a 
little 
Neither 
agree nor 
disagree 
Agree a little Agree quite a 
lot 
Agree 
strongly 
1 2 3 4 5 6 7 
 
 STATEMENTS 
1. Not being able to have bowel movements as often as I would like to 
2. Incomplete bowel movement, like you didn’t “empty” yourself 
3. Passing of stools that were too hard or lumpy 
4. Straining to try to pass stools 
5. Sensation of a blockage or obstruction in your bowel movements 
6. Bloating in your abdomen  
7. Stomach cramps  
8. Rectal burning (during or after a bowel movement) 
9. Hemorrhoids (also known as ‘piles’) 
10. Other (non-Hemorrhoidal) rectal bleeding 
11. Nausea 
12. Vomiting 
 
Q23 
Over the past TWO weeks, to what extent did your constipation symptoms cause you to feel each of the 
following: 
 
RATING: 
Not at all   A moderate amount   A great deal 
1 2 3 4 5 6 7 
 
STATEMENTS 
1. Disgusted  
2. Frustrated 
3. Helpless 
4. Depressed  
5. Dependant and “not free” 
6. Obsessed i.e. not being able to get it out 
of your mind 
7. Anxious or worried 
 
Q24 
Over the past TWO weeks, to what extent did your constipation symptoms cause you to do each of the 
following: 
 
RATING: 
Not at all   A moderate amount   A great deal 
1 2 3 4 5 6 7 
 
STATEMENTS 
1. Spend excessive time in the bathroom 
2. Have difficulty socialising 
3. Have difficulty working (including both paid work, and household chores) 
4. Have difficulty pursuing hobbies 
5. Have difficulty being intimate with others 
6. Have difficulty following your normal routine 
7. Have difficulty taking your opioid drugs as normal 
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Q25a 
Given below are a number of approaches that people use to relieve constipation.  
 
Which of these approaches do you use on a regular basis, if any? There are no right or wrong answers. 
 
1.  Used a single laxative treatment on its own 
2.  Combined multiple laxative treatments 
3.  Rotated among different opioid drug treatments 
4.  Decreased the dose or frequency of your opioid drug treatment(s) 
5.  Skipped a dose of your opioid drug treatment(s) 
6.  Skipped several doses of your opioid drug treatment(s) 
7.  Used an alternative (non opioid) painkiller 
8.  Used manual methods (e.g. using your fingers) to support evacuation 
9.  Drank more water, juice, or other fluids 
10.  Eaten less, or been careful about what you ate 
11.  Obtained additional fibre through your diet (e.g. by eating more fruit, vegetables, or cereal)? 
12.  Taken a fibre supplement product (e.g. Fybogel, or a psyllium or methylcellulose product)   
13.  Exercised more often 
14.  Had colonic hydrotherapy (also known as 'irrigation') 
15.  Used a suppository or enema (a solid or liquid preparation inserted into the rectum) 
16.  Used relaxation techniques (e.g. deep breathing, meditation)  
17.  An approach I devised myself to deal with constipation 
 
Q25b 
Now think back to the last time you experienced severe constipation. Which of the following approaches did 
you use to manage your constipation then? 
 
1.  Used a single laxative treatment on its own 
2.  Combined multiple laxative treatments 
3.  Rotated among different opioid drug treatments 
4.  Decreased the dose or frequency of your opioid drug treatment(s) 
5.  Skipped a dose of your opioid drug treatment(s) 
6.  Skipped several doses of your opioid drug treatment(s) 
7.  Used an altenative (non opioid) painkiller 
8.  Used manual methods (e.g. using your fingers) to support evacuation 
9.  Drank more water, juice, or other fluids 
10.  Eaten less, or been careful about what you ate 
11.  Obtained additional fibre through your diet (e.g. by eating more fruit, vegetables, or cereal)? 
12.  Taken a fibre supplement product (e.g. Fybogel, or a psyllium or methylcellulose product)   
13.  Exercised more often 
14.  Had colonic hydrotherapy (also known as 'irrigation') 
15.  Used a suppository or enema (a solid or liquid preparation inserted into the rectum) 
16.  Used relaxation techniques (e.g. deep breathing, meditation)  
17.  An approach I devised myself to deal with constipation 
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This section asks for further information about the constipation treatments (laxative drugs) that you 
currently use most often. 
 
Q9a 
Given below is a list of treatments that people typically take to help with their bowel movements. 
 
Could you please select the ones that you are currently taking? 
 
 99 I do not take any treatments to help with my bowel movements 
 
INSERT LAXATIVE LIST 
 
Q9b 
Which of these treatments do you rely on the most to help with your bowel movements (i.e. select the one 
you use most routinely to help with bowel movements)? Select one drug from the list 
 
INSERT LAXATIVE LIST 
 
Q26 
To what extent do you disagree or agree with the following statements regarding the laxative drug, 
__________? 
 
RATING 
 
Disagree 
strongly 
Disagree 
quite a lot 
Disagree a 
little 
Neither 
agree nor 
disagree 
Agree a little Agree quite a 
lot 
Agree 
strongly 
1 2 3 4 5 6 7 
 
STATEMENTS 
1. Taking everything into consideration, I am very satisfied with the laxative drug 
2. It allows me to move my bowels more easily 
3. It relieves any pain I experience in moving my bowels 
4. It has no inconvenient or problematic side effects 
5. It is easy to prepare and administer 
6. It is discreet and easy to carry around 
7. It works rapidly to control my constipation symptoms 
8. It is affordable  
9. It works predictably 
10. It represents good value for money 
11. It is available on the National Health Service – or the cost is reimbursed 
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This section asks about your attitudes on a variety of issues relating to opioid drugs, constipation, and your 
health in general. 
 
Q27 
Given below are a number of statements related to your attitudes and beliefs about pain and opioids. There 
are no right or wrong answers. We are interested only in your opinions. 
To what extent do you disagree or agree with the following statements? 
 
RATING: 
 
Disagree 
strongly 
Disagree 
quite a lot 
Disagree a 
little 
Neither 
agree nor 
disagree 
Agree a little Agree quite a 
lot 
Agree 
strongly 
1 2 3 4 5 6 7 
 
STATEMENTS 
1. I feel really overwhelmed by my pain 
2. I am the type of person who likes to get on with my life despite my pain 
3. I would rather suffer a little from pain rather than take pain medications  
4. My opioid drugs have allowed me to live a fuller life 
5. I find it difficult to cope without my opioid drugs  
6. I don’t like my opioid drugs and have them only if it is absolutely necessary 
7. I believe my health will improve and I will be able to discontinue my opioid drugs in the future 
8. I often feel guilty when I take opioid drugs 
9. I think doctors must be more careful than they are while prescribing opioid drugs 
10. I feel that pharmaceutical companies that manufacture opioid drugs are really improving the lives 
of patients  
11. My experience of pain has helped me realise what is truly important 
12. Because of my pain I no longer take people or things for granted 
13. My experience of pain has helped me appreciate the value of living everyday to the full 
14. My experience of pain has made me question who I am as a person 
15.  I wish I could keep using my opioid pain mediation without having the constipation side effects 
16. While opioid drugs relieve pain, the side effects make it difficult to do daily activities 
17. I hate having to balance getting pain relief with constipation side effects 
18. I am unable to control my pain properly because of the constipation side effects 
19. I have a group of supportive people who make it easier to cope with pain 
20. People suffering from pain and other health conditions frequently reach out to me for support 
 
Q28 
Given below are a number of statements related to your attitudes and beliefs about constipation, stomach 
health, and its impact on your life. There are no right or wrong answers. We are interested only in your 
opinions. 
To what extent do you disagree or agree with the following statements? 
 
RATING: 
 
Disagree 
strongly 
Disagree 
quite a lot 
Disagree a 
little 
Neither 
agree nor 
disagree 
Agree a 
little 
Agree 
quite a lot 
Agree 
strongly 
1 2 3 4 5 6 7 
 
STATEMENTS 
 
1. I feel upset if I cannot move my bowels every day 
2. My constipation is awful and overwhelms me 
3. At the back of my mind, I’m always thinking of constipation 
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4. After pain, constipation is one of my most bothersome problems 
5. I often cut down my opioid medication to relieve my constipation 
6. I would prefer not to reduce my opioid medication to relieve my constipation 
7. I often worry that my bowels will lose their ability to function normally 
8. Constipation prevents me from doing things that I really want 
9. I take extreme measures to get relief from constipation that might not be good for me in other ways 
10. Often constipation gets so bad, that I have to combine many different treatments 
11. It bothers me that I spend so much time in the bathroom because of my constipation 
12. Often I am afraid that I will fall in the bathroom and injure myself 
 
Q29 
Given below are a number of statements related to your attitudes and beliefs about treatments that you use 
for constipation. There are no right or wrong answers. We are interested only in your opinions. 
To what extent do you disagree or agree with the following statements? 
 
RATING: 
Disagree 
strongly 
Disagree 
quite a lot 
Disagree a 
little 
Neither 
agree nor 
disagree 
Agree a little Agree quite a 
lot 
Agree 
strongly 
1 2 3 4 5 6 7 
 
STATEMENTS 
1. I would much prefer to take natural (non pharmaceutical) treatments for my constipation 
2. I would much prefer to change my diet, or some other aspect of my lifestyle, rather than 
taking pharmaceutical treatments for constipation 
3. I would much rather take a constipation treatment as and when the need arises rather than 
take it continuously 
4. I would much prefer a constipation treatment that I could use continuously, over the long 
term, as opposed to one that could only be taken when required 
5. For me, it is very important that a constipation treatment works fast 
6. For me, it is very important that a constipation treatment works predictably and not 
at random 
7. For me, it is very important that a constipation treatment can be taken at any time of the day 
8. For me, it is very important that I can take my constipation treatment with or without food 
9. For me, it is very important that my constipation treatment does not affect the pain relief 
that I get from my opioid drugs 
10. For me, it is very important that my constipation treatment does not affect the way that I 
take my opioid drugs (e.g. the timing, the dosage of my opioids) 
11. For me, it is very important that a constipation treatment has no bad side effects 
12. If I were to try a new treatment for constipation, I would rather not have to immediately give 
up using laxative drugs 
13. Having to prepare laxatives is not inconvenient for me 
14. I would much prefer to take an oral pill rather than a liquid treatment to help manage 
my constipation 
15. I am constantly on the look out for new treatments for constipation 
 
Q30 
Given below are a number of statements related to your attitudes and beliefs about the way you manage 
your health. There are no right or wrong answers. We are interested only in your opinions. To what extent 
do you disagree or agree with the following statements? 
 
RATING: 
Disagree 
strongly 
Disagree 
quite a lot 
 Disagree a 
little 
Neither 
agree nor 
disagree 
Agree a 
little 
Agree 
quite a lot 
Agree 
strongly 
1 2  3 4 5 6 7 
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STATEMENTS 
1. I consider myself more knowledgeable than most about my health conditions 
2. I do my own research regarding my health condition(s) and treatments 
3. I strictly follow the regimens that my doctor(s) prescribe 
4. I think it is very important to adapt one’s medication regime oneself rather than follow the 
doctor’s instruction 
5. I would have appreciated additional help from my doctor or medical professional 
regarding constipation  
6. I like to deal with constipation on my own rather than speak to the doctor about it 
7. I wish my doctor would spend more time speaking to me about my constipation problems 
8. I would rather not discuss my constipation with my doctors 
 
This section asks about your personal characteristics and circumstances, and your health. 
 
Q35 
Please indicate your employment status: 
1=Working full-time 
2=Working part-time 
3=Self-employed 
4=Unemployed  
5=Student or in full-time training 
6=Retired 
7=Semi retired 
 
Q36 
To what extent does your work require extensive physical activity (e.g. extensive walking, travelling)? 
 
Not at all   A moderate 
amount 
  A great deal 
1 2 3 4 5 6 7 
 
Q36b 
How long, on average, does your regular commute to work take? 
1=Less than 15 minutes 
2=More than 15 minutes but less than 30 minutes 
3=More than 30 minutes but less than one hour  
4=More than one hour but less than 90 minutes 
5=More than 90 minutes but less than two hours 
6=More than two hours 
 
Q37 
What is your total household income (£)? Your household includes all of the people who you live with. 
1=0-9,999 
2=10,000-24,999 
3=25,000-39,999 
4=40,000-54,999 
5=55,000-69,999 
6=70,000-84,999 
7=85,000-99,999 
8=100,000 or more 
96 – Prefer not to say 
 
Q38 
Which of the following best represents your relationship status? 
1=Single (i.e. not currently in a 
relationship rather than legal 
status) 
2=In a relationship 
3=Civil Partnership 
4=Married 
5=Separated 
6=Divorced 
7=Widowed 
96 – Prefer not to say 
 
Q39 
Do you have any children? 
1=Yes 2=No  
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Q40 
Are your children still at home or independent? 
1=Under 18 and still at home 
2=Adult children still at home 
3=Mix of independent and still at home 
4=Independent 
 
Q41 
In a typical week, how many hours per day do you spend reading/listening/watching the following…?  
 
RATING 
1=Not at all 
2=Less than an hour 
3=1-2 hours 
4=3-5 hours 
5=6-10 hours 
6=More than 10 hours 
 
STATEMENTS 
1. TV 
2. Radio 
3. Magazines 
4. Newspapers 
5. Internet 
 
Q41a 
At what time of day do you typically watch TV? Select all that apply 
1=Morning 
2=Afternoon 
3=Evening/ night 
 
Q41b 
How do you typically watch TV? Select all that apply 
1=Live (as it happens) 
2=Catch-up (via a set top Box) 
3=Online via TV channel website 
 
Q41c 
What technology do you typically use to watch TV? Select all that apply 
1=A regular TV set 
2=A laptop computer 
3=An ipad or tablet  
4=A desktop computer 
5=A smartphone 
 
Q41d 
Which of the following newspapers do you read on a regular basis (e.g. at least once per week)? Select all 
that apply. 
 
COUNTRY SPECIFIC LIST e.g. 
1=The Guardian 
2=The Times 
3=The Daily Telegraph 
4=The Financial Times 
5=The i (concise newspaper) 
6=Metro 
7=The Daily Mail 
8=The Daily Express 
9=The Sun 
10=The Daily Mirror 
11=The Daily Star 
12=The Daily Record 
13=Evening Standard 
98=Other (please specify) 
 
Q42 
Which of the following social networking platforms and sites do you use on a regular basis? Select all that 
apply 
1. Facebook 
2. Copains d’Avant SHOW IN FRANCE ONLY 
3. Tuenti SHOW IN SPAIN ONLY 
4. LinkedIn 
5. Viadeo SHOW IN FRANCE ONLY 
6. XING SHOW IN GERMANY ONLY 
7. Twitter 
8. Instagram 
9. WhatsApp 
10. Google+ 
11.  Snapchat 
98 – other (please specify) 
99 - None 
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Q43 
Where do you get information and advice regarding health issues/concerns? Select all that apply 
1. Healthcare professionals (including doctors and nurses) 
2. Your partner  
3. Other family member(s) 
4. My friend(s) 
5. Leaflets in my doctor’s surgery 
6. Library / books / literature 
7. Newspaper/ Magazines 
8. Television 
9. Radio 
10. Online search engines like Google 
11. Online health forums 
12. Online blogs 
13. Other online sources  
99. None of these 
 
Q44 
Please indicate which, if any, of the following conditions you have? 
Select as many as apply 
 
1=Diabetes 
2=Diverticulosis 
3=Thyroid disturbance 
4=Stroke 
5=Multiple Sclerosis 
6=Back pain or spinal injury  
7=Anxiety 
8=Depression 
9=Heart Disease 
10=Osteoporosis 
11=Arthritis/ Rheumatism 
12=Respiratory diseases (e.g. asthma,  
       COPD, emphysema, chronic bronchitis) 
13=Cancer 
96=Prefer not to say 
99=None of the above 
 
Q45 
Do you have a full-time carer? 
1=Yes 
2=No 
 
Q46 
To what extent does your carer help you to manage your constipation? 
Not at all   A moderate 
amount 
  A great deal 
1 2 3 4 5 6 7 
 
Q47 
To what extent do you see yourself as: 
 
RATING 
Not at all   A moderate 
amount 
  A great deal 
1 2 3 4 5 6 7 
 
STATEMENTS 
1. Extraverted, enthusiastic 
2. Critical, quarrelsome 
3. Dependable, self-disciplined 
4. Anxious, easily upset 
5. Open to new experiences, complex 
6. Reserved, quiet 
7. Sympathetic, warm 
8. Disorganized, careless 
9. Calm, emotionally stable  
10. Conventional, uncreative 
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Q48 
Which of the following options best describes the effect of your chronic pain on your daily life? Select one 
option only. 
1. I am fully active just like I was before the onset of chronic pain 
2. I’m restricted in physically strenuous activity but can walk around, and able to carry out 
work of a light or sedentary nature, e.g., light house work, office work 
3. I can walk around, and am capable of taking care of myself. I am unable to carry out any 
work activities, and be up and about more than 50% of waking hours 
4. I am completely disabled. I cannot look after myself and I am confined to a bed or chair 
all of the time. 
 
Q49 
Which of the following activities do you do to help distract you from your pain, or to cope better with it? 
Select all that apply. 
 
1. Watching TV programmes 
2. Meeting friends and family socially 
3. Connecting with friends on social networks (e.g., Whatsapp, Facebook) 
4. Connecting with other people who are suffering from similar health conditions either in person or 
through social networks 
5. Practising an art (e.g., drawing, photography, singing, playing and instrument) 
6. Playing a sport (football, tennis, etc.) 
7. Playing an indoor game 
8. Watching movies 
9. Watching sports events 
10. Do research and learn new things (e.g., learn a new language, take an online course) 
11. Doing cardiovascular exercises (running, aerobics, etc.) 
12. Doing mind-body exercises (e.g., Yoga,  Tai-Chi, Alexander Technique) 
13. Physiotherapy 
14. Going for walks 
15. Spending time with nature 
16. Going to watch music events 
17. Going to the museum 
18. Doing shopping 
19. Writing about my experience (e.g., writing a blog or a diary) 
20. Meeting a counsellor, a mentor or a coach 
99. None of these 
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